

Appendix A.

All Results

- Study Dir 1
- Study Dir 2
- Study Dir 3
- Study Dir 4
- Study Dir 5
- Study Dir 6
- Study Rep 01
- Study Rep 02
- Study Rep 03
- Study Rep 04
- Study Rep 05
- Study Rep 06
- Study Rep 07
- Study Rep 08
- Study Rep 09
- Study Rep 10
- Study Rep 11
- Study Rep 12
- Study Rep 13
- Study Rep 14
- Study Rep 15
- Study Rep 16
- Study Rep 17
- Study Rep 18
- Study Rep 19
- Study Rep 20
- Study Rep 21
- Study Rep 22
- Study Rep 23
- Study Rep 24
- Study Rep 25
- Study Rep 26
- Study Rep 27
- Study Rep 28
- Study Rep 29
- Study Rep 30
- Study Rep 31
- Study Rep 32

- Study Rep 33
- Study Rep 34
- Study Rep 35
- Study Rep 36
- Study Rep 37
- Study Rep 38
- Study Rep 39
- Study Rep 40

Study Dir 1

Comparison of Table 1 Values for Study Dir 1

Variable	Exp				Study			Ref	
	Study Exp	Aet Exp	Exp Diff	Std Diff	Study Ref	Aet Ref	Ref Diff	Std Diff	Diff of Diff
Number of patients	687,637	691,272	-3,635	-	985,653	1,001,665	-16,012	-	12,377
Age	51.2	50.9	0.3	0.0	51.7	51.7	-0.0	-0.0	0.4
Combined Comorbidity Score	-0.1	-0.1	-0.0	-0.0	0.2	0.2	0.0	0.0	-0.0
Number of Unique Generics Dispensed	3.5	3.6	-0.1	-0.0	4.3	4.5	-0.2	-0.0	0.1
Number of Filled Rx	8.0	8.4	-0.4	-0.0	10.2	10.8	-0.6	-0.0	0.2
Number of inpatient hospital encounters (IP)	0.1	0.1	0.0	0.1	0.1	0.1	-0.0	-0.1	0.1
Number of non-acute institutional encounters (IS)	0.0	-	-	-	0.0	-	-	-	-
Number of emergency room encounters (ED)	0.2	0.2	0.0	0.0	0.2	0.2	-0.0	-0.0	0.0

Number of ambulatory encounters (AV)	4.3	4.8	-0.5	-0.1	5.9	6.7	-0.8	-0.1	0.2
Number of other ambulatory encounters (OA)	0.0	0.3	-0.3	-0.1	0.2	0.4	-0.2	-0.1	-0.1
0-44	27%	27%	1%	-	27%	25%	2%	-	-1%
45-54	34%	33%	0%	-	28%	28%	1%	-	-0%
55-64	32%	32%	0%	-	34%	34%	1%	-	-0%
65-150	7%	8%	-1%	-	11%	12%	-2%	-	1%
Gender (F)	40%	40%	-0%	-	51%	51%	-0%	-	0%
Allergic Reactions	8%	6%	1%	-	9%	7%	2%	-	-0%
Diabetes	21%	21%	0%	-	13%	14%	-0%	-	0%
Heart Failure	1%	0%	1%	-	3%	1%	2%	-	-1%
Ischemic Heart Disease	4%	4%	-0%	-	12%	13%	-0%	-	0%
NSAID	11%	10%	2%	-	12%	10%	2%	-	-0%

Comparison of Health Results for Study Dir 1 (DT1)

Basic Parameters

Outcome	Parameter	Study Exp	Action Exp	Study Ref	Action Ref
Angioedema	Number of outcomes	176	163	216	206
Angioedema	Number of patients	687,637	691,272	985,653	1,001,665
Angioedema	Number of person-years	530,301	508,374	850,164	818,770
Angioedema	Risk per 1000	0.26	0.24	0.22	0.21
Angioedema	Incidence rate per 1000	0.33	0.32	0.25	0.25

Treatment Effect Estimates

Outcome	Parameter	Study Value	Study CI	Action Value	Action CI
Angioedema	Unadjusted estimate	1.27	(1.04, 1.55)	1.24	(1.03, 1.45)

Angioedema	Adjusted estimate	1.46	(1.19, 1.80)	1.41	(1.20, 1.62)
------------	-------------------	------	--------------	------	--------------

Study Dir 2

Comparison of Table 1 Values for Study Dir 2

Variable	Study		Exp		Study		Ref		Diff
	Exp	Aet Exp	Diff	Std Diff	Ref	Aet Ref	Diff	Std Diff	
Number of patients	333,603	334,506	-903	-	410,139	414,724	-4,585	-	3,682
Age	50.7	50.3	0.4	0.0	50.1	50.1	0.0	0.0	0.3
Combined Comorbidity Score	-0.1	-0.1	-0.0	-0.0	0.3	0.3	0.0	0.0	-0.0
Number of Unique Generics Dispensed	3.4	3.7	-0.3	-0.1	4.3	4.7	-0.4	-0.1	0.1
Number of Filled Rx	7.7	8.5	-0.8	-0.1	9.9	11.0	-1.1	-0.1	0.3
Number of inpatient hospital encounters (IP)	0.1	0.1	0.0	0.0	0.2	0.2	-0.0	-0.0	0.0
Number of non-acute institutional encounters (IS)	0.0	0.1	-0.1	-0.1	0.1	0.1	-0.0	-0.0	-0.0
Number of emergency room encounters (ED)	0.2	0.2	-0.0	-0.0	0.3	0.3	0.0	0.0	-0.0
Number of ambulatory encounters (AV)	5.2	5.8	-0.6	-0.1	8.0	8.6	-0.6	-0.0	0.0
Number of other ambulatory encounters (OA)	0.2	0.4	-0.2	-0.1	0.3	0.6	-0.3	-0.1	0.1
0-44	29%	29%	0%	-	33%	32%	1%	-	-0%
45-54	34%	33%	0%	-	28%	27%	0%	-	-0%

55-64	31%	30%	0%	-	31%	30%	0%	-	-0%
65-150	6%	7%	-1%	-	9%	10%	-1%	-	1%
Gender (F)	41%	41%	-0%	-	53%	53%	-0%	-	-0%
Allergic Reactions	10%	8%	2%	-	12%	10%	2%	-	-0%
Diabetes	23%	23%	-0%	-	14%	14%	-0%	-	0%
Heart Failure	1%	0%	1%	-	4%	2%	2%	-	-1%
Ischemic Heart Disease	4%	4%	-0%	-	13%	14%	-0%	-	0%
NSAID	14%	12%	2%	-	15%	13%	2%	-	-0%

Comparison of Health Results for Study Dir 2 (DT2)

Basic Parameters

Outcome	Parameter	Study Exp	Action Exp	Study Ref	Action Ref
Angioedema	Number of outcomes	70	66	45	45
Angioedema	Number of patients	333,603	334,506	410,139	414,724
Angioedema	Number of person-years	172,083	166,091	201,603	195,311
Angioedema	Risk per 1000	0.21	0.20	0.11	0.11
Angioedema	Incidence rate per 1000	0.41	0.40	0.22	0.23

Treatment Effect Estimates

Outcome	Parameter	Study Value	Study CI	Action Value	Action CI
Angioedema	Unadjusted estimate	1.85	(1.27, 2.68)	1.75	(1.37, 2.13)
Angioedema	Adjusted estimate	2.43	(1.62, 3.65)	2.34	(1.93, 2.75)

Study Dir 3

Comparison of Table 1 Values for Study Dir 3

Variable	Study	Aet	Exp	Exp	Ref				
	Exp	Exp	Diff	Std Diff	Study Ref	Aet Ref	Ref Diff	Std Diff	Diff of Diff
Number of patients	92,596	95,633	-3,037	-	2,530,418	2,552,384	-21,966	-	18,929
Age	51.9	51.2	0.7	0.1	41.5	41.0	0.5	0.0	0.3
Number of Unique Generics Dispensed	4.9	5.2	-0.3	-0.1	3.0	3.2	-0.2	-0.1	-0.1
Number of Filled Rx	11.5	12.4	-0.9	-0.1	6.6	7.2	-0.6	-0.1	-0.3
Number of inpatient hospital encounters (IP)	0.1	0.1	-0.0	-0.0	0.1	0.1	0.0	0.0	-0.0
Number of non-acute institutional encounters (IS)	0.1	0.1	-0.0	-0.0	0.0	0.0	-0.0	-0.0	-0.0
Number of emergency room encounters (ED)	0.4	0.4	-0.0	-0.0	0.3	0.3	0.0	0.0	-0.0
Number of ambulatory encounters (AV)	8.2	9.8	-1.6	-0.1	5.1	5.9	-0.8	-0.1	-0.8
Number of other ambulatory encounters (OA)	0.4	0.7	-0.3	-0.1	0.2	0.3	-0.1	-0.0	-0.2
Age 0-44	27%	26%	2%	-	57%	51%	6%	-	-4%
Age 45-54	28%	28%	-0%	-	23%	23%	-0%	-	-0%
Age 55-64	33%	34%	-1%	-	17%	17%	-0%	-	-1%
Age 65-150	12%	11%	1%	-	3%	3%	0%	-	1%
Female	56%	56%	-0%	-	57%	57%	-0%	-	-0%
Combined Comorbidity Score	0%	-	-	-	-	-	-	-	-
Angina	1%	1%	0%	-	0%	0%	0%	-	0%
Congestive Heart Failure	1%	0%	1%	-	0%	0%	0%	-	1%
Diabetes	11%	11%	-0%	-	7%	7%	-0%	-	-0%

GI bleed	2%	2%	0%	-	1%	1%	-0%	-	0%
Hypertension	30%	30%	0%	-	17%	17%	-0%	-	0%
Ischemic Heart Disease	5%	5%	0%	-	0%	2%	-2%	-	2%
OA	21%	22%	-0%	-	5%	5%	-0%	-	0%
Peptic Ulcer Disease	0%	0%	-0%	-	0%	0%	-0%	-	-0%
RA	2%	3%	-0%	-	1%	1%	-0%	-	-0%
Clopidogrel	2%	2%	0%	-	1%	1%	-0%	-	0%
PPI	16%	17%	-1%	-	7%	8%	-0%	-	-1%
Statin	22%	23%	-1%	-	12%	12%	-0%	-	-0%
Warfarin	3%	3%	0%	-	0%	0%	-0%	-	0%

Comparison of Health Results for Study Dir 3 (DT3)

Basic Parameters

Outcome	Parameter	Study Exp	Action Exp	Study Ref	Action Ref
GI Bleed	Number of outcomes	137	135	1,420	1,478
GI Bleed	Number of patients	92,596	95,633	2,530,418	2,552,384
GI Bleed	Number of person-years	22,136	22,885	393,315	388,528
GI Bleed	Risk per 1000	1.48	1.41	0.56	0.58
GI Bleed	Incidence rate per 1000	6.19	5.90	3.61	3.80

Treatment Effect Estimates

Outcome	Parameter	Study Value	Study CI	Action Value	Action CI
GI Bleed	Unadjusted estimate	1.64	(1.37, 1.96)	1.49	(1.31, 1.67)
GI Bleed	Adjusted estimate	1.04	(0.87, 1.25)	0.86	(0.68, 1.05)

Study Dir 4

Comparison of Table 1 Values for Study Dir 4

Variable	Study				Ref		Diff		
	Exp	Aet Exp	Exp Diff	Exp Std Diff	Study Ref	Aet Ref	Ref Diff	Ref Std Diff	Ref of Diff
Number of patients	253,528	253,513	15	-	422,025	422,601	-576	-	591
Age	53.7	53.4	0.3	0.0	52.9	52.7	0.2	0.0	0.1
Combined Comorbidity Score	0.1	0.0	0.1	0.1	0.0	0.0	-0.0	-0.0	0.1
Number of Unique Generics Dispensed	4.1	4.4	-0.3	-0.1	3.8	4.1	-0.3	-0.1	-0.1
Number of Filled Rx	9.5	10.4	-0.9	-0.1	8.8	9.5	-0.7	-0.1	-0.2
Number of inpatient hospital encounters (IP)	0.1	0.5	-0.4	-0.2	0.1	0.5	-0.4	-0.2	-0.0
Number of non-acute institutional encounters (IS)	0.0	0.0	-0.0	-0.0	0.0	0.0	-0.0	-0.0	0.0
Number of emergency room encounters (ED)	0.2	0.2	-0.0	-0.0	0.2	0.2	-0.0	-0.0	-0.0
Number of ambulatory encounters (AV)	6.2	7.3	-1.1	-0.1	5.9	6.9	-1.0	-0.1	-0.1
Number of other ambulatory encounters (OA)	0.3	0.4	-0.1	-0.0	0.2	0.4	-0.2	-0.1	0.1
0-44	19%	19%	0%	-	21%	21%	0%	-	-0%
45-54	34%	34%	0%	-	35%	34%	0%	-	0%
55-64	38%	38%	0%	-	36%	36%	0%	-	-0%
65-150	9%	10%	-1%	-	8%	9%	-1%	-	0%
Gender (F)	40%	40%	-0%	-	46%	46%	-0%	-	0%
Atrial fibrillation	2%	2%	-0%	-	2%	2%	-0%	-	0%
Chest pain	13%	13%	-0%	-	11%	11%	-0%	-	0%
Conduction Disorders	1%	1%	-0%	-	1%	1%	-0%	-	0%

Congestive Heart Failure	2%	2%	-0%	-	2%	2%	-0%	-	0%
CVD symptoms	6%	6%	-0%	-	6%	6%	-0%	-	0%
Depression	6%	6%	0%	-	7%	7%	-0%	-	0%
Diabetes	24%	24%	-0%	-	22%	22%	-0%	-	-0%
Hypertension	49%	49%	-0%	-	45%	45%	-0%	-	0%
Ischemic Heart Disease	14%	14%	-0%	-	7%	7%	-0%	-	0%
Disorders of Lipid Metabolism	68%	68%	0%	-	61%	61%	0%	-	-0%
Prior MI	1%	1%	-0%	-	1%	1%	-0%	-	-0%
Peripheral Vasc Disease	2%	3%	-0%	-	2%	2%	-0%	-	0%
Post Surgical Aortocoronary Bypass	1%	1%	-0%	-	0%	1%	-0%	-	0%
Stroke TIA	3%	3%	-0%	-	3%	3%	-0%	-	0%

Comparison of Health Results for Study Dir 4 (DT4)

Basic Parameters

Outcome	Parameter	Study Exp	Action Exp	Study Ref	Action Ref
ACS Hospitalization	Number of outcomes	597	575	725	711
ACS Hospitalization	Number of patients	253,528	253,513	422,025	422,601
ACS Hospitalization	Number of person-years	133,252	127,460	241,780	232,198
ACS Hospitalization	Risk per 1000	2.35	2.27	1.72	1.68
ACS Hospitalization	Incidence rate per 1000	4.48	4.51	3.00	3.06

Treatment Effect Estimates

Outcome	Parameter	Study Value	Study CI	Action Value	Action CI
ACS Hospitalization	Unadjusted estimate	1.45	(1.30, 1.62)	1.43	(1.32, 1.54)
ACS Hospitalization	Adjusted estimate	1.16	(1.04, 1.30)	1.18	(1.06, 1.29)

Study Dir 5

Comparison of Table 1 Values for Study Dir 5

Variable	Study Exp	Aet Exp	Exp Diff	Exp Std Diff	Study Ref	Aet Ref	Ref Diff	Ref Std Diff	Diff of Diff
Number of subjects	6,598	6,039	559	-	13,872	13,929	-57	-	616
Sex, female	56%	56%	0%	-	57%	57%	0%	-	-0%
Race, white	85%	85%	-0%	-	85%	85%	-0%	-	-0%
Race, black	10%	10%	-0%	-	9%	9%	0%	-	-0%
Race, other	5%	5%	0%	-	5%	5%	0%	-	0%
Age group, < 70	36%	34%	2%	-	35%	33%	2%	-	-0%
Age group, 70-79	34%	35%	-1%	-	36%	36%	-0%	-	-0%
Age group, 80+	29%	31%	-2%	-	29%	31%	-2%	-	0%
Comorbidity, high cholesterol	55%	59%	-4%	-	56%	60%	-4%	-	0%
Comorbidity, hypertension	93%	95%	-2%	-	94%	95%	-2%	-	-0%
Comorbidity, previous ischemic heart disease	74%	77%	-3%	-	76%	79%	-4%	-	1%
Comorbidity, diabetes	83%	84%	-1%	-	84%	86%	-1%	-	1%

Comparison of Health Results for Study Dir 5 (DT5)

Basic Parameters

Outcome	Parameter	Study Exp	Aetion Exp	Study Ref	Aetion Ref
Angina	Number of outcomes	1,195	869	2,517	2,027
Angina	Number of patients	6,598	6,039	13,872	13,929
Angina	Number of person-years	-	6,055	-	13,967
Angina	Risk per 1000	181.12	143.90	181.44	145.52

Angina	Incidence rate per 1000	-	143.50	-	145.13
Any cardiac event	Number of outcomes	5,287	4,711	11,370	11,169
Any cardiac event	Number of patients	6,598	6,039	13,872	13,929
Any cardiac event	Number of person-years	-	6,055	-	13,967
Any cardiac event	Risk per 1000	801.30	780.10	819.64	801.85
Any cardiac event	Incidence rate per 1000	-	777.96	-	799.66
Heart failure	Number of outcomes	3,505	3,102	7,536	7,476
Heart failure	Number of patients	6,598	6,039	13,872	13,929
Heart failure	Number of person-years	-	6,055	-	13,967
Heart failure	Risk per 1000	531.22	513.66	543.25	536.72
Heart failure	Incidence rate per 1000	-	512.26	-	535.26
Ischemic heart disease	Number of outcomes	4,723	4,114	10,228	9,840
Ischemic heart disease	Number of patients	6,598	6,039	13,872	13,929
Ischemic heart disease	Number of person-years	-	6,055	-	13,967
Ischemic heart disease	Risk per 1000	715.82	681.24	737.31	706.44
Ischemic heart disease	Incidence rate per 1000	-	679.38	-	704.51

Treatment Effect Estimates

Outcome	Parameter	Study Value	Study CI	Action Value	Action CI
Angina	Unadjusted estimate	0.98	(0.93, 1.04)	0.99	(0.90, 1.07)
Angina	Adjusted estimate	-	(-, -)	1.01	(0.92, 1.10)
Any cardiac event	Unadjusted estimate	0.97	(0.93, 1.00)	0.88	(0.80, 0.95)
Any cardiac event	Adjusted estimate	-	(-, -)	0.91	(0.83, 0.99)
Heart failure	Unadjusted estimate	0.97	(0.93, 1.01)	0.91	(0.85, 0.97)
Heart failure	Adjusted estimate	0.98	(0.93, 1.05)	0.94	(0.88, 1.00)
Ischemic heart disease	Unadjusted estimate	0.96	(0.93, 1.00)	0.89	(0.82, 0.95)
Ischemic heart disease	Adjusted estimate	-	(-, -)	0.92	(0.85, 0.98)

Study Dir 6

Comparison of Table 1 Values for Study Dir 6

Variable	Study	Aet	Diff	Std Diff
Number of patients	315,495	317,945	-2,450	-
Age	-	73.5	-	-
Sex (Male)	43%	43%	0%	-
Sex (Female)	57%	57%	-0%	-
Race (White)	84%	84%	-0%	-
Race (Black)	11%	11%	0%	-
Race (Other)	5%	5%	0%	-
Alzheimer or related disorders or senile	52%	50%	2%	-
Heart failure	75%	74%	1%	-
Chronic kidney disease	59%	56%	3%	-
Cancer-female breast/colorectal/prostate/lung	19%	16%	3%	-
Chronic obstructive pulmonary disease (COPD)	51%	48%	3%	-
Depression	50%	45%	5%	-
Diabetes	79%	63%	17%	-
Ischemic heart disease	87%	85%	2%	-
Osteoporosis	33%	33%	1%	-
Rheumatoid arthritis or osteoarthritis (RA/OA)	36%	32%	4%	-
Stroke/Transient ischemic attack	20%	14%	5%	-

Study Rep 01

Comparison of Table 1 Values for Study Rep 01

Variable	Study Exp	Aet Exp	Exp Diff	Exp Std Diff	Study Ref	Aet Ref	Ref Diff	Ref Std Diff	Diff of Diff
Number of patients	1,329	1,245	84	-	4,190	3,889	301	-	-217
Age; mean (sd)	51.1	51.0	0.1	0.0	46.4	46.1	0.3	0.0	-0.2
Age < 20	11%	12%	-1%	-	18%	15%	3%	-	-4%
Age 20 - 40	9%	8%	1%	-	18%	17%	1%	-	0%
Age 40 - 60	46%	47%	-1%	-	38%	41%	-3%	-	2%
Age 60 - 80	33%	32%	1%	-	25%	26%	-1%	-	2%
Age > 80	1%	1%	-0%	-	1%	1%	0%	-	-0%
Ex Smoker	13%	-	-	-	15%	-	-	-	-
Missing Smoking	33%	-	-	-	34%	-	-	-	-
Never Smoker	35%	-	-	-	35%	-	-	-	-
Current Smoker	18%	-	-	-	15%	-	-	-	-
Klinefelter's Syndrome	2%	2%	0%	-	4%	5%	-1%	-	1%
Hypogonadism	3%	6%	-3%	-	10%	12%	-2%	-	-0%
Erectile Dysfunction	13%	15%	-2%	-	13%	15%	-2%	-	-0%
CVD	11%	-	-	-	10%	-	-	-	-
Hypertension	17%	18%	-1%	-	16%	20%	-4%	-	2%
Diabetes	8%	11%	-3%	-	11%	14%	-3%	-	0%
Asthma or COPD	12%	14%	-2%	-	14%	15%	-1%	-	-0%
Alcohol Abuse	6%	3%	3%	-	6%	4%	2%	-	1%
Index Year 1988-1993	21%	11%	10%	-	19%	7%	12%	-	-2%
Index Year 1994-1997	31%	22%	9%	-	17%	12%	5%	-	3%

Index Year 1998-2001	24%	31%	-7%	-	21%	24%	-3%	-	-3%
Index Year 2002-2005	15%	22%	-7%	-	22%	29%	-7%	-	-0%
Index Year 2006-2009	9%	15%	-6%	-	22%	29%	-7%	-	1%
BMI <20	3%	2%	1%	-	2%	3%	-1%	-	2%
BMI 20 - 25	15%	24%	-9%	-	17%	22%	-5%	-	-4%
BMI 26 - 30	23%	24%	-1%	-	27%	21%	6%	-	-7%
BMI 30+	18%	16%	2%	-	13%	23%	-10%	-	12%
BMI Unknown	42%	-	-	-	41%	-	-	-	-
Never smoker	35%	40%	-5%	-	35%	41%	-6%	-	1%
Current smoker	15%	17%	-2%	-	18%	17%	1%	-	-3%
Past smoker	15%	18%	-3%	-	13%	18%	-5%	-	2%
Unknown smoking status	34%	-	-	-	33%	-	-	-	-

Comparison of Health Results for Study Rep 01 (RS01)

Basic Parameters

Outcome	Parameter	Study Exp	Aetion Exp	Study Ref	Aetion Ref
Prostate Cancer	Number of outcomes	28	35	48	66
Prostate Cancer	Number of patients	1,329	1,245	4,190	3,889
Prostate Cancer	Number of person-years	11,412	13,448	27,052	35,774
Prostate Cancer	Risk per 1000	21.07	28.11	11.46	16.97
Prostate Cancer	Incidence rate per 1000	2.45	2.60	1.77	1.84

Treatment Effect Estimates

Outcome	Parameter	Study Value	Study CI	Aetion Value	Aetion CI
Prostate Cancer	Unadjusted estimate	1.38	(0.87, 2.20)	1.40	(0.99, 1.81)

Prostate Cancer Adjusted estimate 1.08 (0.68, 1.71) - (-, -)

Study Rep 02

Comparison of Table 1 Values for Study Rep 02

Variable	Study		Exp Diff	Exp Std Diff	Ref			Ref Std Diff	Diff of Diff
	Exp	Aet Exp			Study Ref	Aet Ref	Ref Diff		
Number of patients	45,510	163,493	-117,983	-	349,529	1,268,234	-918,705	-	800,722
Number of office visits; mean (sd)	9.0	7.5	1.5	0.2	8.5	6.9	1.6	0.2	-0.1
Number of distinct (3-digit) diagnoses; mean (SD)	6.7	-	-	-	6.6	-	-	-	-
Number of distinct prescription classes; mean (SD)	6.2	-	-	-	5.7	-	-	-	-
Number of hospitalizations; mean (sd)	0.1	0.1	-0.0	-0.1	0.2	0.1	0.1	0.1	-0.1
Male	48%	52%	-4%	-	49%	51%	-2%	-	-1%
Use of Anti-arrhythmic	1%	-	-	-	1%	-	-	-	-
Use of ACE or ARB	24%	22%	3%	-	25%	22%	3%	-	-0%
Use of anti-anginals	5%	3%	2%	-	5%	2%	3%	-	-1%
Use of beta blocker	19%	18%	1%	-	19%	17%	2%	-	-1%
Use of CCB	13%	10%	3%	-	14%	11%	3%	-	-0%
Use of loop diuretics	6%	4%	2%	-	6%	4%	2%	-	0%
Use of thiazide diuretics	2%	2%	0%	-	2%	2%	0%	-	0%

Use of thiazide diuretics	7%	7%	2%	-	10%	8%	2%	-	-0%
Use of digoxin	2%	1%	1%	-	2%	1%	1%	-	-0%
Use of non-statin lipid lowering agent	14%	5%	9%	-	6%	3%	4%	-	5%
Use of heparin	0%	1%	-0%	-	0%	1%	-0%	-	-0%
Use of coumarins	3%	2%	1%	-	3%	2%	1%	-	-0%
Use of platelet inhibitors	4%	5%	-0%	-	4%	3%	1%	-	-1%
Use of PVD drugs	1%	-	-	-	1%	-	-	-	-
Use of estrogen	13%	6%	7%	-	12%	6%	6%	-	1%
Diabetes	22%	23%	-1%	-	23%	23%	-0%	-	-1%
Heart valve disorder	4%	5%	-1%	-	5%	5%	0%	-	-1%
Myocarditis	1%	0%	1%	-	2%	0%	1%	-	-0%
Hypertension	43%	50%	-7%	-	41%	49%	-8%	-	1%
Coronary atherosclerosis	13%	13%	-0%	-	14%	10%	4%	-	-5%
Pulmonary heart disease	0%	0%	0%	-	1%	0%	0%	-	-0%
Other heart disease	2%	-	-	-	2%	-	-	-	-
Conduction disorder	10%	1%	8%	-	10%	1%	9%	-	-0%
V-fib, V-flutter, cardiac arrest	0%	0%	-0%	-	0%	0%	0%	-	-0%
Heart failure	2%	1%	1%	-	3%	1%	2%	-	-1%
TIA/Other CVD	2%	-	-	-	3%	-	-	-	-
Late effects of CVD	0%	-	-	-	1%	-	-	-	-
Peripheral atherosclerosis/aneurysm	3%	-	-	-	4%	-	-	-	-
Arterial embolism	0%	0%	0%	-	0%	0%	0%	-	-0%
Phlebitis	1%	1%	0%	-	1%	1%	1%	-	-0%
COPD	6%	6%	1%	-	6%	6%	0%	-	0%
Rheumatoid arthritis	1%	1%	0%	-	1%	1%	0%	-	0%
Osteoarthritis	9%	11%	-2%	-	9%	11%	-2%	-	0%
Disease AMI	2%	2%	0%	-	1%	2%	1%	-	1%

Prior AMI	2%	2%	-0%	-	4%	2%	1%	-	-1%
Prior Cerebrovascular Event	4%	1%	3%	-	5%	2%	3%	-	-0%
Prior Unstable angina	2%	2%	0%	-	3%	2%	1%	-	-1%
Prior CABG	1%	1%	0%	-	1%	1%	1%	-	-1%
Prior Coronary angioplasty	0%	0%	-0%	-	0%	0%	0%	-	-0%
Prior Coronary atherectomy and transmyocardial rev	0%	0%	-0%	-	0%	0%	-0%	-	-0%
Prior Coronary stent procedure	2%	3%	-0%	-	3%	2%	1%	-	-1%
Prior Carotid revascularization	0%	0%	0%	-	0%	0%	0%	-	-0%
Hospitalizations	11%	10%	1%	-	15%	12%	3%	-	-2%

Comparison of Health Results for Study Rep 02 (RS02)

Basic Parameters

Outcome	Parameter	Study Exp	Aetion Exp	Study Ref	Aetion Ref
Acute MI	Number of outcomes	120	642	1,054	6,270
Acute MI	Number of patients	45,510	163,493	349,529	1,268,234
Acute MI	Number of person-years	29,350	129,756	236,586	1,137,609
Acute MI	Risk per 1000	2.64	3.93	3.02	4.94
Acute MI	Incidence rate per 1000	4.09	4.95	4.46	5.51
Coronary & cerebrovascular events	Number of outcomes	924	4,468	8,698	37,735
Coronary & cerebrovascular events	Number of patients	45,510	163,493	349,529	1,268,234
Coronary & cerebrovascular	Number of person-	28,936	126,992	232,408	1,111,934

events	years				
Coronary & cerebrovascular events	Risk per 1000	20.30	27.33	24.88	29.75
Coronary & cerebrovascular events	Incidence rate per 1000	31.93	35.18	37.43	33.94
Coronary event	Number of outcomes	722	3,761	3,313	29,743
Coronary event	Number of patients	45,510	163,493	349,529	1,268,234
Coronary event	Number of person-years	29,035	127,396	233,449	1,117,600
Coronary event	Risk per 1000	15.86	23.00	9.48	23.45
Coronary event	Incidence rate per 1000	24.87	29.52	14.19	26.61

Treatment Effect Estimates

Outcome	Parameter	Study Value	Study CI	Aetion Value	Aetion CI
Acute MI	Unadjusted estimate	0.91	(0.75, 1.10)	0.88	(0.80, 0.96)
Acute MI	Adjusted estimate	1.06	(0.87, 1.28)	0.90	(0.81, 0.98)
Coronary & cerebrovascular events	Unadjusted estimate	0.84	(0.78, 0.90)	0.99	(0.96, 1.02)
Coronary & cerebrovascular events	Adjusted estimate	0.99	(0.92, 1.06)	0.98	(0.95, 1.01)
Coronary event	Unadjusted estimate	0.86	(0.79, 0.92)	1.06	(1.02, 1.09)
Coronary event	Adjusted estimate	1.01	(0.93, 1.09)	1.00	(0.97, 1.04)

Study Rep 03

Comparison of Table 1 Values for Study Rep 03

Variable	Study Exp	Aet Exp	Exp Diff	Exp Std Diff	Study Ref	Aet Ref	Ref Diff	Ref Std Diff	Diff of Diff
Number of patients	775	2,294	-1,519	-	958	4,246	-3,288	-	1,769
Charlson index	0.5	0.7	-0.2	-0.2	0.4	1.0	-0.6	-0.4	0.4
Any hospitalization	131.0	0.4	130.6	10.9	242.0	0.6	241.4	13.6	-110.8
Outpatient visits	15.0	7.9	7.1	0.8	13.0	6.9	6.1	0.7	1.0
Number of Rx	17.0	25.2	-8.2	-0.5	13.0	21.8	-8.8	-0.6	0.6
Age 0 - 20	5%	5%	0%	-	8%	5%	3%	-	-3%
Age 21 - 40	40%	37%	3%	-	38%	31%	7%	-	-4%
Age 41 - 64	55%	53%	2%	-	53%	50%	3%	-	-0%
Female	79%	81%	-2%	-	59%	64%	-5%	-	3%
Male	21%	19%	2%	-	41%	36%	5%	-	-3%
Northeast Region	11%	20%	-9%	-	14%	22%	-8%	-	-1%
North Central Region	24%	23%	1%	-	32%	24%	8%	-	-7%
South Region	49%	40%	9%	-	40%	34%	6%	-	3%
West Region	15%	15%	0%	-	14%	18%	-4%	-	4%
Crohn's Disease	55%	58%	-3%	-	55%	55%	0%	-	-3%
Ulcerative Colitis	43%	48%	-5%	-	44%	51%	-7%	-	2%
Indeterminate	1%	-	-	-	1%	-	-	-	-
Seizure diagnosis	5%	4%	1%	-	12%	11%	1%	-	0%
Migraine	37%	34%	3%	-	9%	11%	-2%	-	5%
Bipolar disorder	12%	17%	-5%	-	24%	27%	-3%	-	-2%
Obesity	3%	7%	-4%	-	1%	4%	-3%	-	-0%
Peripheral neuropathy	3%	0%	3%	-	1%	1%	0%	-	2%
Congenital brain	0%	-	-	-	0%	-	-	-	-

abnormality

IBS	6%	9%	-3%	-	5%	7%	-2%	-	-0%
Weight loss	1%	3%	-2%	-	2%	5%	-3%	-	0%
Malnutrition	1%	1%	-0%	-	1%	3%	-2%	-	2%
Anemia	5%	7%	-2%	-	6%	7%	-1%	-	-0%
5-ASA	73%	39%	34%	-	75%	39%	36%	-	-1%
6MP/AZA	28%	14%	14%	-	28%	13%	15%	-	-1%
Methotrexate	3%	3%	0%	-	2%	2%	0%	-	-0%
Cyclosporine	1%	1%	-0%	-	1%	1%	-0%	-	-0%
Enteral budesonide	13%	-	-	-	11%	-	-	-	-
Rectal steroid	5%	1%	4%	-	1%	1%	-1%	-	4%
Any biologic	21%	15%	6%	-	17%	14%	3%	-	3%
Infliximab	15%	9%	6%	-	12%	7%	5%	-	2%
Adalimumab	6%	6%	0%	-	5%	6%	-1%	-	1%
Certolizumab	0%	1%	-1%	-	0%	1%	-1%	-	0%
Natalizumab	0%	0%	-0%	-	0%	0%	-0%	-	0%
EGD (upper)	13%	16%	-3%	-	11%	15%	-4%	-	1%
Colonoscopy (lower)	31%	30%	1%	-	29%	28%	1%	-	1%
Any endoscopy	38%	37%	1%	-	36%	37%	-1%	-	1%

Comparison of Health Results for Study Rep 03 (RS03)

Basic Parameters

Outcome	Parameter	Study Exp	Aetion Exp	Study Ref	Aetion Ref
Steroid use	Number of outcomes	-	676	-	1,238
Steroid use	Number of patients	775	2,294	958	4,246
Steroid use	Number of person-years	-	867	-	1,859
Steroid use	Risk per 1000	-	294.68	-	291.57
Steroid use	Incidence rate per 1000	-	779.21	-	665.75

Treatment Effect Estimates

Outcome	Parameter	Study Value	Study CI	Action Value	Action CI
Steroid use	Unadjusted estimate	1.05	(0.73, 1.52)	1.08	(0.99, 1.18)
Steroid use	Adjusted estimate	1.14	(0.74, 1.73)	0.98	(0.88, 1.08)

Study Rep 04

Comparison of Table 1 Values for Study Rep 04

Variable	Study Exp	Aet Exp	Exp Diff	Exp Std Diff	Study Ref	Aet Ref	Ref Diff	Ref Std Diff	Diff of Diff
Number of subjects	3,825	5,466	-1,641	-	21,728	34,455	-12,727	-	11,086
Age, mean	46.2	50.5	-4.3	-0.3	42.1	49.8	-7.6	-0.5	3.3
Women	65%	64%	1%	-	55%	54%	0%	-	1%
Arthritis	27%	17%	9%	-	24%	20%	4%	-	5%
Back pain	23%	25%	-2%	-	13%	16%	-2%	-	1%
Benzodiazepine use	19%	16%	3%	-	14%	12%	2%	-	1%
Drug abuse excluding opioids	1%	2%	-1%	-	3%	5%	-2%	-	1%
Mood/anxiety disorders and depression	10%	10%	-0%	-	10%	11%	-1%	-	1%
Fractures	2%	3%	-0%	-	7%	6%	0%	-	-1%
Headaches	5%	7%	-3%	-	4%	6%	-2%	-	-1%
Malignancy	15%	10%	6%	-	20%	15%	5%	-	1%
Musculoskeletal pain	25%	-	-	-	23%	-	-	-	-

Other	1%	-	-	-	1%	-	-	-	-
Reproductive system pain	2%	-	-	-	2%	-	-	-	-
Visceral pain	8%	-	-	-	13%	-	-	-	-
Wound injury	1%	-	-	-	4%	-	-	-	-
Neuropathy	4%	6%	-2%	-	2%	3%	-1%	-	-1%

Comparison of Health Results for Study Rep 04 (RS04)

Basic Parameters

Outcome	Parameter	Study Exp	Aetion Exp	Study Ref	Aetion Ref
Opioid abuse	Number of outcomes	12	12	105	123
Opioid abuse	Number of patients	21,728	5,466	3,825	34,455
Opioid abuse	Number of person-years	-	5,445	-	34,291
Opioid abuse	Risk per 1000	0.55	2.20	27.45	3.57
Opioid abuse	Incidence rate per 1000	-	2.20	-	3.59

Treatment Effect Estimates

Outcome	Parameter	Study Value	Study CI	Aetion Value	Aetion CI
Opioid abuse	Unadjusted estimate	0.65	(0.32, 1.20)	0.61	(0.02, 1.21)
Opioid abuse	Adjusted estimate	0.42	(0.22, 0.79)	0.67	(0.07, 1.27)

Study Rep 05

Comparison of Table 1 Values for Study Rep 05

Study	Aet	Exp	Exp Std	Study	Aet	Ref	Ref Std	Diff of
-------	-----	-----	---------	-------	-----	-----	---------	---------

Variable	Exp	Exp	Diff	Diff	Ref	Ref	Diff	Diff	Diff
Number of subjects	3,069	2,976	93	-	6,893	6,255	638	-	-545
Age, mean	64.0	62.5	1.5	-	-	62.1	-	-	-
Men	40%	41%	-1%	-	48%	48%	-0%	-	-0%
Charlson comorbidity index = 0	54%	15%	39%	-	49%	11%	38%	-	1%
Charlson comorbidity index = 1	36%	12%	24%	-	40%	11%	29%	-	-5%
Charlson comorbidity index = 2	7%	24%	-16%	-	9%	23%	-14%	-	-2%
Charlson comorbidity index = 3+	3%	49%	-46%	-	3%	55%	-52%	-	6%
Health Plan = PPO	51%	51%	-0%	-	54%	54%	-0%	-	0%
Health Plan = Comprehensive	23%	21%	2%	-	23%	21%	2%	-	-0%
Health Plan = HMO	15%	16%	-1%	-	13%	14%	-1%	-	-0%
Health Plan = POS	6%	6%	-0%	-	6%	7%	-1%	-	0%
Health Plan = CDHP	2%	3%	-1%	-	2%	2%	-1%	-	-0%
Health Plan = EPI	1%	2%	-1%	-	1%	1%	-0%	-	-1%
Health Plan = HDHP	1%	1%	0%	-	1%	1%	-0%	-	0%
Epidural anesthesia	28%	25%	3%	-	53%	53%	-0%	-	4%

Study Rep 06

Comparison of Table 1 Values for Study Rep 06

Exp

Ref Diff

Variable	Study Exp	Aet Exp	Exp Diff	Std Diff	Study Ref	Aet Ref	Ref Diff	Std Diff	of Diff
Number of subjects	19,760	17,652	2,108	-	12,261	15,770	-3,509	-	5,617
Age, mean	-	46.3	-	-	-	37.8	-	-	-
Men	100%	100%	0%	-	100%	100%	0%	-	0%
Onset of epilepsy (dx) prior to start of follow-up (AED rx)	84%	77%	7%	-	80%	78%	2%	-	5%
1993-1995	32%	16%	16%	-	15%	9%	6%	-	10%
1996-1998	16%	11%	6%	-	13%	8%	5%	-	1%
1999-2001	22%	16%	6%	-	22%	15%	6%	-	-1%
2002-2004	16%	34%	-19%	-	22%	34%	-11%	-	-8%
2005-2008	14%	23%	-9%	-	27%	34%	-7%	-	-2%
Fall in last 3 years	3%	4%	-1%	-	4%	3%	1%	-	-2%
Fracture in last 3 years	21%	6%	14%	-	20%	6%	14%	-	1%
Malnutrition, malabsorption, or liver disease	3%	0%	3%	-	3%	0%	2%	-	0%
Hyperthyroidism, hyperparathyroidism, or hypogonadism	0%	0%	0%	-	0%	0%	0%	-	-0%
Diabetes mellitus	4%	5%	-1%	-	4%	5%	-1%	-	-0%
Osteoporosis	1%	1%	0%	-	0%	0%	0%	-	0%
Arthritis	12%	8%	4%	-	11%	7%	4%	-	-0%
Stroke or TIA	13%	7%	5%	-	11%	7%	4%	-	2%
Cancer	12%	8%	4%	-	10%	7%	3%	-	0%
Non-epilepsy nervous system and sense organ diseases	44%	-	-	-	48%	-	-	-	-
Mental disorders	34%	-	-	-	36%	-	-	-	-
Corticosteroids	5%	5%	-0%	-	4%	5%	-1%	-	1%
Osteoporosis treatments	1%	1%	0%	-	2%	1%	1%	-	-0%
Dementia treatments	0%	0%	0%	-	0%	0%	0%	-	-0%
Drugs used in psychoses and	8%	6%	2%	-	7%	6%	1%	-	1%

Drug used in psychosis and related disorders	3%	3%	2%	-	1%	3%	1%	-	1%
Hypnotics and anxiolytics	15%	13%	2%	-	14%	13%	1%	-	1%
Tricyclic and related anti-depressants	6%	4%	1%	-	6%	4%	2%	-	-1%
Other anti-depressants	7%	6%	0%	-	9%	7%	2%	-	-1%
Opioid analgesics	17%	13%	3%	-	16%	13%	4%	-	-0%
Other analgesics	32%	34%	-2%	-	33%	32%	1%	-	-3%
Parkinson's medications	5%	2%	3%	-	4%	2%	3%	-	0%
Medications used for nutrition and blood disorders	11%	-	-	-	11%	-	-	-	-

Comparison of Health Results for Study Rep 06 (RS06M)

Basic Parameters

Outcome	Parameter	Study Exp	Action Exp	Study Ref	Action Ref
Fracture	Number of outcomes	2,286	1,432	1,033	1,143
Fracture	Number of patients	19,760	17,652	12,261	15,770
Fracture	Number of person-years	95,027	57,751	45,106	42,678
Fracture	Risk per 1000	115.69	81.12	84.25	72.48
Fracture	Incidence rate per 1000	24.06	24.80	22.90	26.78

Treatment Effect Estimates

Outcome	Parameter	Study Value	Study CI	Action Value	Action CI
Fracture	Unadjusted estimate	1.05	(0.96, 1.15)	0.94	(0.86, 1.02)
Fracture	Adjusted estimate	1.09	(0.98, 1.20)	0.95	(0.87, 1.03)

Study Rep 07

Comparison of Table 1 Values for Study Rep 07

Variable	Exp				Study			Ref	
	Study Exp	Aet Exp	Exp Diff	Std Diff	Study Ref	Aet Ref	Ref Diff	Std Diff	Diff of Diff
Number of subjects	20,058	18,175	1,883	-	244,497	281,698	-37,201	-	39,084
Age, mean	-	52.4	-	-	-	49.7	-	-	-
Total costs, mean (paper reports median)	3,236.0	12,104.6	-8,868.6	-	1,661.0	11,013.0	-9,352.0	-	483.4
Men	46%	46%	-0%	-	50%	47%	3%	-	-3%
Overweight/obesity	21%	19%	2%	-	13%	11%	2%	-	1%
Neuropathy, nephropathy, or retinopathy	16%	24%	-9%	-	8%	11%	-3%	-	-6%
Insulin use	28%	28%	-0%	-	10%	8%	3%	-	-3%
Chronic pancreatitis	0%	0%	0%	-	0%	0%	0%	-	-0%

Comparison of Health Results for Study Rep 07 (RS07)

Basic Parameters

Outcome	Parameter	Study Exp	Aetion Exp	Study Ref	Aetion Ref
Acute pancreatitis	Number of outcomes	47	52	472	568
Acute pancreatitis	Number of patients	20,058	18,175	244,497	281,698
Acute pancreatitis	Number of person-years	25,072	24,577	305,621	364,550
Acute pancreatitis	Risk per 1000	2.34	2.86	1.93	2.02
Acute pancreatitis	Incidence rate per 1000	1.87	2.12	1.54	1.56

Treatment Effect Estimates

Outcome	Parameter	Study Value	Study CI	Aetion Value	Aetion CI
---------	-----------	-------------	----------	--------------	-----------

Acute pancreatitis	Unadjusted estimate	1.21	(-, -)	1.36	(1.07, 1.64)
Acute pancreatitis	Adjusted estimate	1.10	(0.81, 1.49)	1.09	(0.79, 1.39)

Study Rep 08

Comparison of Table 1 Values for Study Rep 08

Variable	Study Exp	Aet Exp	Exp Diff	Exp Std Diff	Study Ref	Aet Ref	Ref Diff	Ref Std Diff	Diff of Diff
Number of subjects	776	1,280	-504	-	1,919	1,588	331	-	-835
Number PS-matched subjects	737	-	-	-	737	-	-	-	-
Age, mean	37.5	38.6	-1.1	-	37.7	37.2	0.5	-	-1.7
Charlson comorbidity index, mean	0.3	0.3	0.0	0.0	0.3	0.3	0.0	0.0	-0.0
Men	66%	42%	23%	-	63%	30%	33%	-	-10%
Psychiatric Hospitalization	24%	17%	7%	-	25%	19%	6%	-	1%
Diabetes	5%	5%	0%	-	6%	8%	-2%	-	2%
Hyperlipidemia	17%	20%	-3%	-	18%	19%	-1%	-	-2%
Carbamazapine	3%	1%	2%	-	4%	3%	1%	-	1%
Lamotrigine	16%	13%	3%	-	16%	24%	-8%	-	11%
Lithium	14%	14%	0%	-	14%	13%	1%	-	-1%
Oxcarbazepine	8%	4%	4%	-	9%	7%	2%	-	2%
Topirimate	9%	6%	4%	-	9%	8%	1%	-	3%
Valproate	22%	14%	7%	-	21%	15%	6%	-	1%

Comparison of Health Results for Study Rep 08 (RS08)

Basic Parameters

Outcome	Parameter	Study Exp	Action Exp	Study Ref	Action Ref
Psych hospitalization	Number of outcomes	-	73	-	61
Psych hospitalization	Number of patients	776	1,280	1,919	1,588
Psych hospitalization	Number of person-years	-	279	-	359
Psych hospitalization	Risk per 1000	-	57.03	-	38.41
Psych hospitalization	Incidence rate per 1000	-	260.93	-	169.87

Treatment Effect Estimates

Outcome	Parameter	Study Value	Study CI	Action Value	Action CI
Psych hospitalization	Unadjusted estimate	1.55	(1.10, 2.18)	1.52	(1.18, 1.86)
Psych hospitalization	Adjusted estimate	1.55	(1.10, 2.18)	1.86	(1.50, 2.22)

Study Rep 09

Comparison of Table 1 Values for Study Rep 09

Variable	Study Exp	Aet Exp	Exp Diff	Exp Std Diff	Study Ref	Aet Ref	Ref Diff	Ref Std Diff	Diff of Diff
Number of subjects	776	3,270	-2,494	-	2,497	1,580	917	-	-3,411
Number PS-matched subjects	770	-	-	-	770	-	-	-	-
Age, mean	37.1	38.1	-1.0	-0.1	36.5	37.1	-0.6	-0.1	-0.4
Charlson comorbidity index, mean	0.2	0.3	-0.1	-0.1	0.2	0.3	-0.1	-0.1	-0.0

Men	67%	35%	32%	-	70%	30%	40%	-	-8%
Psychiatric Hospitalization	23%	24%	-1%	-	23%	19%	4%	-	-5%
Diabetes	6%	7%	-1%	-	5%	8%	-3%	-	2%
Hyperlipidemia	17%	18%	-1%	-	17%	19%	-2%	-	0%
Carbamazepine	4%	3%	1%	-	4%	2%	1%	-	-0%
Lamotrigine	18%	22%	-4%	-	17%	24%	-7%	-	3%
Lithium	15%	16%	-1%	-	14%	13%	1%	-	-3%
Oxcarbazepine	10%	6%	4%	-	9%	7%	2%	-	2%
Topiramate	10%	7%	3%	-	11%	8%	3%	-	1%
Valproate	21%	15%	6%	-	22%	15%	6%	-	-0%

Study Rep 10

Comparison of Table 1 Values for Study Rep 10

Variable	Study	Aet	Diff	Std Diff
Number of subjects	1,417	1,974	-557	-
Mean age (SD)	52.2	51.6	0.6	0.1
Time to warfarin initiation from index VTE claim	13.1	-	-	-
Baseline ECI Score	2.1	1.8	0.3	0.2
Female	47%	48%	-2%	-
PE as index VTE event	17%	13%	4%	-
History of Cancer	10%	-	-	-

Study Rep 11

Comparison of Table 1 Values for Study Rep 11

Variable	Study			Exp	Study			Ref	
	Exp	Aet Exp	Exp Diff	Std Diff	Ref	Aet Ref	Ref Diff	Std Diff	Diff of Diff
Number of subjects	25,719	19,809	5,910	-	234,536	183,826	50,710	-	-44,800
Number of Physician Visits	6.9	8.8	-1.9	-	5.4	7.2	-1.8	-	-0.1
Total Costs	7,473.0	16,594.9	-9,121.9	-	7,386.0	15,629.9	-8,243.9	-	-878.1
Number of Drugs Dispensed	11.0	11.1	-0.1	-	6.7	5.2	1.5	-	-1.6
Age 0-34	5%	5%	0%	-	13%	17%	-5%	-	5%
Age 35-44	16%	16%	1%	-	17%	19%	-2%	-	3%
Age 45-54	34%	35%	-1%	-	28%	27%	1%	-	-1%
Age 55-64	36%	37%	-1%	-	30%	26%	5%	-	-5%
Age 65+	8%	8%	0%	-	12%	11%	2%	-	-1%
Female	56%	56%	-0%	-	49%	53%	-4%	-	4%
Northeast	8%	7%	0%	-	10%	9%	1%	-	-0%
Midwest	22%	26%	-4%	-	24%	27%	-3%	-	-0%
South	57%	55%	2%	-	52%	50%	2%	-	1%
West	13%	12%	1%	-	15%	14%	1%	-	-0%
Neuropathy	10%	13%	-3%	-	4%	4%	0%	-	-3%
Renal Impairment/Dialysis	4%	3%	1%	-	4%	2%	2%	-	-1%
Retinopathy	5%	8%	-3%	-	3%	2%	1%	-	-4%
Hypertension	64%	72%	-8%	-	49%	48%	1%	-	-9%
Hyperlipidemia	77%	76%	1%	-	54%	47%	8%	-	-7%

Ischemic Heart Disease	13%	16%	-3%	-	11%	10%	0%	-	-3%
MI	1%	2%	-1%	-	2%	2%	-0%	-	-0%
CHF	3%	4%	-1%	-	4%	3%	0%	-	-1%
Stroke	2%	3%	-1%	-	2%	3%	-1%	-	-1%
Alcohol Use/Abuse	0%	0%	-0%	-	1%	1%	-0%	-	0%
Smoking	2%	3%	-1%	-	3%	4%	-2%	-	1%
Overweight/Obesity	19%	19%	-0%	-	10%	11%	-1%	-	1%
Cholecystitis	1%	1%	-0%	-	1%	1%	-0%	-	-0%
Cholelithiasis	1%	0%	1%	-	1%	0%	1%	-	0%
Prior Cholecystectomy	1%	1%	0%	-	0%	1%	-0%	-	0%
Endoscopic Retrograde Cholangiopancreatography	0%	0%	-0%	-	0%	0%	0%	-	-0%
Class I drugs	52%	52%	-0%	-	41%	39%	3%	-	-3%
Class II drugs	55%	56%	-2%	-	42%	40%	3%	-	-4%
Fibrates	13%	14%	-1%	-	6%	4%	2%	-	-3%
Statins	54%	58%	-4%	-	33%	23%	10%	-	-14%
ACE Inhibitors	42%	44%	-2%	-	29%	20%	9%	-	-11%
ARBs	28%	29%	-1%	-	15%	12%	4%	-	-5%
Antipsychotics	1%	2%	-0%	-	1%	1%	-0%	-	-0%
Non-Alcohol Sedatives	17%	20%	-3%	-	12%	13%	-1%	-	-2%
Non-Steroidal Anti- Inflammatory Drugs	23%	21%	2%	-	18%	16%	2%	-	0%
Acid-Suppressing Drugs	18%	20%	-2%	-	13%	12%	1%	-	-2%

Comparison of Health Results for Study Rep 11 (RS11)

Basic Parameters

Outcome	Parameter	Study Exp	Action Exp	Study Ref	Action Ref
Acute pancreatitis	Number of outcomes	35	58	520	410

Acute pancreatitis	Number of patients	25,719	19,809	234,536	183,826
Acute pancreatitis	Number of person-years	17,630	22,536	254,868	201,582
Acute pancreatitis	Risk per 1000	1.36	2.93	2.22	2.23
Acute pancreatitis	Incidence rate per 1000	1.99	2.57	2.04	2.03

Treatment Effect Estimates

Outcome	Parameter	Study Value	Study CI	Action Value	Action CI
Acute pancreatitis	Unadjusted estimate	1.00	(0.70, 1.40)	1.27	(0.99, 1.54)
Acute pancreatitis	Adjusted estimate	0.90	(0.30, 1.30)	1.03	(0.71, 1.34)

Study Rep 12

Comparison of Table 1 Values for Study Rep 12

Variable	Study Exp	Aet Exp	Exp Diff	Exp Std Diff	Study Ref	Aet Ref	Ref Diff	Ref Std Diff	Diff of Diff
Total sample	506	898	-392	-	612	1,751	-1,139	-	747
Age	59.5	58.9	0.6	0.1	58.5	58.7	-0.2	-0.0	0.8
Charlson comorbidity index score	2.4	1.7	0.6	0.3	1.9	2.1	-0.2	-0.1	0.8
Mean overall statin MPR (SD)	0.7	-	-	-	0.7	-	-	-	-
Gender = Male	63%	58%	4%	-	47%	51%	-4%	-	9%
Gender = Female	37%	42%	-4%	-	53%	49%	4%	-	-9%
Age 18-24 years	0%	0%	-0%	-	0%	0%	-0%	-	-0%
Age 25-34 years	1%	2%	-0%	-	2%	2%	-0%	-	-0%
Age 35-44 years	7%	8%	-2%	-	9%	8%	1%	-	-2%

Age 45–54 years	24%	23%	1%	-	25%	25%	-0%	-	1%
Age 55–64 years	37%	39%	-2%	-	37%	37%	1%	-	-2%
Age 65+ years	31%	27%	4%	-	27%	28%	-1%	-	4%
Northeast	48%	11%	37%	-	47%	12%	35%	-	2%
South	6%	46%	-41%	-	8%	48%	-41%	-	0%
Midwest	9%	26%	-17%	-	7%	24%	-17%	-	-0%
West	8%	17%	-9%	-	6%	16%	-10%	-	1%
National/other	30%	0%	30%	-	32%	0%	32%	-	-2%
Health plan type = HMO	41%	12%	29%	-	34%	12%	22%	-	7%
Health plan type = Indemnity	13%	11%	2%	-	13%	11%	2%	-	-0%
Health plan type = PPO	30%	20%	10%	-	38%	15%	23%	-	-13%
Health plan type = POS	11%	46%	-35%	-	10%	49%	-39%	-	4%
Health plan type = Other	5%	11%	-6%	-	4%	12%	-8%	-	2%
Payer type = Commercial payer	85%	99%	-14%	-	89%	99%	-10%	-	-4%
Payer type = Medicaid	3%	1%	1%	-	4%	1%	3%	-	-2%
Payer type = Medicare	13%	0%	13%	-	7%	0%	7%	-	6%
Phenytoin	72%	-	-	-	0%	-	-	-	-
Phenobarbital	6%	-	-	-	0%	-	-	-	-
Carbamazepine	18%	-	-	-	0%	-	-	-	-
Topiramate >=200 mg	3%	-	-	-	0%	-	-	-	-
Oxcarbazepine >=1200 mg	1%	-	-	-	0%	-	-	-	-
Lamotrigine	0%	-	-	-	7%	-	-	-	-
Gabapentin	0%	-	-	-	57%	-	-	-	-
Levetiracetam	0%	-	-	-	8%	-	-	-	-
Pregabalin	0%	-	-	-	0%	-	-	-	-
Zonisamide	0%	-	-	-	2%	-	-	-	-

Valproate	0%	-	-	-	19%	-	-	-	-
Topiramate <200 mg	0%	-	-	-	1%	-	-	-	-
Oxcarbazepine <1200 mg	0%	-	-	-	5%	-	-	-	-
Mean MPR for initiated AED (SD)	33%	-	-	-	34%	-	-	-	-
Adherent to initiated AED	42%	-	-	-	35%	-	-	-	-
Atorvastatin	77%	-	-	-	80%	-	-	-	-
Simvastatin	17%	-	-	-	16%	-	-	-	-
Lovastatin	6%	-	-	-	5%	-	-	-	-
Adherent to statin	48%	-	-	-	45%	-	-	-	-

Comparison of Health Results for Study Rep 12 (RS12)

Basic Parameters

Outcome	Parameter	Study Exp	Action Exp	Study Ref	Action Ref
Statin polypharmacy	Number of outcomes	30	82	36	181
Statin polypharmacy	Number of patients	506	898	612	1,751
Statin polypharmacy	Number of person-years	-	861	-	1,666
Statin polypharmacy	Risk per 1000	59.29	91.31	58.82	103.37
Statin polypharmacy	Incidence rate per 1000	-	95.23	-	108.59

Treatment Effect Estimates

Outcome	Parameter	Study Value	Study CI	Action Value	Action CI
Statin polypharmacy	Unadjusted estimate	1.00	(0.77, 1.32)	0.87	(0.60, 1.15)
Statin polypharmacy	Adjusted estimate	-	(-, -)	0.90	(0.62, 1.17)

Study Rep 13

Comparison of Table 1 Values for Study Rep 13

Variable	Study	Aet	Diff	Std Diff
Number of subjects	120,790	112,511	8,279	-
Age 18 to < 40	23%	20%	3%	-
Age 40 to < 50	23%	23%	1%	-
Age 50+	54%	58%	-4%	-
Female	46%	44%	3%	-
Midwest	31%	29%	2%	-
Northeast	10%	9%	1%	-
South	47%	49%	-3%	-
West	12%	13%	-0%	-
ESAs	3%	1%	3%	-
Iron	2%	0%	1%	-
Red blood cell transfusions (>=1)	2%	3%	-1%	-
Anemia	22%	22%	0%	-
ASHD	17%	18%	-0%	-
AMI	3%	3%	-1%	-
CHF	11%	13%	-2%	-
CVA/TIA	5%	8%	-3%	-
PVD	9%	13%	-4%	-
Dysrhythmia	10%	14%	-5%	-
Other CVD	14%	18%	-4%	-
Hypertension	54%	63%	-8%	-
Hyperlipidemia	32%	41%	-9%	-
COPD	10%	13%	-3%	-

GI disorders	4%	3%	1%	-
Liver disease	4%	7%	-3%	-
Diabetes	35%	34%	1%	-
Anticoagulants/antiplatelets	10%	9%	0%	-
Nephrologist (1 + visits)	34%	28%	6%	-

Study Rep 14

Comparison of Table 1 Values for Study Rep 14

Variable	Study	Aet	Diff	Std Diff
Number of subjects	177,885	116,716	61,169	-
Observation period, days, mean (SD)	491.2	-	-	-
Age, years, mean (SD)	54.6	54.1	0.5	0.0
Outpatient services, costs, dollars, mean (SD)	9,990.1	-	-	-
Inpatient services, costs, dollars, mean (SD)	11,258.9	0.0	11,258.9	0.7
Pharmacy costs, costs, dollars, mean (SD)	2,355.2	4,065.8	-1,710.6	-0.2
VTE - DVT only	74%	-	-	-
VTE - PE only	15%	-	-	-
VTE - PE and DVT	11%	-	-	-
Female	57%	56%	2%	-
New England	22%	4%	18%	-
South Atlantic	18%	27%	-9%	-
Middle Atlantic	22%	8%	14%	-
East North Central	11%	18%	-7%	-

West South Central	9%	12%	-2%	-
Mountain	7%	9%	-2%	-
West North Central	5%	13%	-8%	-
East South Central	3%	4%	-2%	-
Pacific	3%	5%	-2%	-
Other Region	0%	0%	0%	-
PPO	29%	15%	14%	-
HMO	29%	21%	8%	-
POS	38%	46%	-8%	-
Other Insurance	4%	1%	4%	-
MI major risk factors	71%	87%	-16%	-
Age 65+	24%	23%	0%	-
Male	43%	44%	-2%	-
Hypertension	46%	52%	-6%	-
Diabetes mellitus	18%	21%	-3%	-
Hyperlipidemia	39%	44%	-5%	-
Cardiovascular disease	40%	43%	-3%	-
Angina pectoris	4%	4%	-0%	-
Previous MI	2%	3%	-1%	-
Coronary artery disease	15%	18%	-3%	-
Stroke/TIA	10%	12%	-2%	-
Left ventricular hypertrophy	6%	8%	-2%	-
Atrial fibrillation	7%	10%	-3%	-
Family history of cardiovascular disease	1%	2%	-1%	-
Chronic kidney disease	6%	8%	-2%	-
Obesity	8%	11%	-3%	-
Smoking	6%	10%	-5%	-
Major risk factors=0	19%	-	-	-

Major risk factors=1	22%	-	-	-
Major risk factors=2	18%	-	-	-
Major risk factors>=3	41%	-	-	-
Exploratory risk factors	33%	55%	-23%	-
Atherosclerosis	5%	7%	-1%	-
Acute respiratory infections	29%	30%	-2%	-
Hypothyroidism	0%	3%	-3%	-
Bacteraemia	1%	2%	-1%	-
Chronic obstructive pulmonary disease	14%	16%	-3%	-
Rheumatoid arthritis	3%	3%	0%	-
Substance abuse	6%	10%	-4%	-
Social risk factors	0%	1%	-0%	-
Stress	0%	1%	-0%	-
NSAIDS	24%	25%	-1%	-
Calcium channel blockers	12%	15%	-3%	-
Beta blockers	20%	22%	-1%	-
Anti-coagulants	11%	14%	-3%	-
Anti-platelets	5%	6%	-0%	-
Anti-hyperlipidemics	26%	28%	-2%	-
Anti-hypertensives	29%	46%	-17%	-
2005 Index	28%	33%	-5%	-
2006 Index	24%	24%	0%	-
2007 Index	25%	23%	2%	-
2008 Index	23%	20%	3%	-

Study Rep 15

Comparison of Table 1 Values for Study Rep 15

Variable	Study	Aet	Diff	Std Diff
Number of subjects	1,935,552	2,089,749	-154,197	-
Age 0-4	22%	28%	-7%	-
Age 5-9	29%	-	-	-
Age 10-14	30%	-	-	-
Age 15-17	19%	17%	2%	-
Male	51%	51%	0%	-
Female	49%	49%	-0%	-

Study Rep 16

Comparison of Table 1 Values for Study Rep 16

Variable	Study	Aet	Diff	Std Diff
Number of subjects	5,086	6,577	-1,491	-
Age Median, Mean, SD	48.3	47.2	1.2	0.2
Charlson comorbidity score, mean (SD)	1.8	0.8	0.9	0.6
Female	34%	36%	-2%	-
Male	66%	64%	2%	-
Age < 18	0%	0%	0%	-
Age 18	1%	1%	-0%	-

Age 25	3%	4%	-1%	-
Age 35	21%	26%	-5%	-
Age 45	56%	56%	0%	-
Age 55	17%	12%	5%	-
Age 65+	1%	1%	0%	-
Northeast	60%	10%	51%	-
South	23%	54%	-31%	-
Midwest	9%	23%	-14%	-
West	7%	13%	-5%	-
Unknown Region	0%	0%	-0%	-
HMO	40%	38%	2%	-
POS	17%	30%	-13%	-
PPO	41%	21%	20%	-
Ind	2%	0%	2%	-
Other Insurance	1%	11%	-10%	-
Commercial	98%	97%	1%	-
Medicaid	0%	3%	-3%	-
Medicare	0%	0%	0%	-
Peginterferon alfa-2a plus ribavirin	48%	38%	10%	-
Peginterferon alfa-2b plus ribavirin	44%	45%	-1%	-
Peginterferon alfa-2a monotherapy	3%	6%	-3%	-
Peginterferon alfa-2b monotherapy	3%	10%	-7%	-
Consensus interferon regimen with ribavirin	2%	2%	0%	-

Study Rep 17

Comparison of Table 1 Values for Study Rep 17

Variable	Study	Aet	Diff	Std Diff
Number of subjects	221	306	-85	-
Age	39.1	38.2	0.9	0.1
Charlson comorbidity index	1.2	1.0	0.2	0.1
Physician office visits	8.2	9.8	-1.6	-0.1
Hospitalizations LOS, days	7.8	2.1	5.7	0.8
Mean total healthcare charges	30,177.0	52,018.9	-21,841.9	-0.2
Mean medical charges	28,248.0	50,102.5	-21,854.5	-0.2
Mean pharmacy charges	1,929.0	1,916.3	12.7	0.0
Female	62%	60%	2%	-
East	16%	16%	0%	-
Midwest	21%	20%	1%	-
South	52%	52%	-0%	-
West	11%	12%	-1%	-
Bone marrow biopsy	51%	45%	6%	-
Hospitalizations=0	74%	76%	-2%	-
Hospitalizations=1	19%	19%	-0%	-
Hospitalizations=2	4%	3%	1%	-
Hospitalizations=3+	3%	2%	1%	-
ED visits=0	94%	94%	0%	-
ED visits=1	3%	2%	1%	-
ED visits=2+	3%	4%	-2%	-

Study Rep 18

Comparison of Table 1 Values for Study Rep 18

Variable	Study	Aet	Diff	Std Diff
Number of subjects	912	1,156	-244	-
Age	68.7	67.9	0.8	0.1
Charlson comorbidity index	2.7	1.8	0.9	-
Physician office visits	10.5	11.3	-0.8	-0.1
Hospitalizations LOS, days	9.0	2.4	6.6	0.5
Mean total healthcare charges	31,832.0	42,260.8	-10,428.8	-0.1
Mean medical charges	29,581.0	39,916.7	-10,335.7	-0.1
Mean pharmacy charges	2,251.0	2,344.1	-93.1	-0.0
Female	52%	51%	2%	-
East	10%	10%	0%	-
Midwest	22%	21%	1%	-
South	51%	50%	1%	-
West	17%	19%	-2%	-
Bone marrow biopsy	45%	43%	3%	-
Hospitalizations=0	71%	72%	-2%	-
Hospitalizations=1	19%	20%	-1%	-
Hospitalizations=2	5%	6%	-0%	-
Hospitalizations=3+	5%	2%	3%	-
ED visits=0	95%	95%	0%	-
ED visits=1	2%	2%	-1%	-
ED visits=2+	3%	3%	0%	-

Study Rep 19

Comparison of Table 1 Values for Study Rep 19

Variable	Study	Aet	Diff	Std Diff
Age	67.4	63.6	3.8	0.3
Male	59%	60%	-1%	-
Age group 40-59	27%	36%	-9%	-
Age group 60-64	12%	16%	-4%	-
Age group 65-69	12%	10%	2%	-
Age group 70-74	13%	17%	-3%	-
Age group 75+	36%	21%	15%	-

Study Rep 20

Comparison of Table 1 Values for Study Rep 20

Variable	Study	Aet	Diff	Std Diff
Age	66.0	62.6	3.4	0.3
Male	57%	58%	-1%	-
Age group 40-59	34%	41%	-7%	-
Age group 60-64	12%	16%	-4%	-
Age group 65-69	10%	9%	1%	-
Age group 70-74	12%	12%	-1%	-

Age group 75+	32%	21%	10%	-
---------------	-----	-----	-----	---

Study Rep 21

Comparison of Table 1 Values for Study Rep 21

Variable	Study	Aet	Diff	Std Diff
Age	69.3	65.2	4.1	0.4
Male	60%	62%	-3%	-
Age group 40-59	23%	29%	-6%	-
Age group 60-64	12%	17%	-4%	-
Age group 65-69	12%	11%	1%	-
Age group 70-74	14%	24%	-10%	-
Age group 75+	38%	19%	19%	-

Study Rep 22

Comparison of Table 1 Values for Study Rep 22

Variable	Study	Aet	Diff	Std Diff
Number of subjects	16,063	20,318	-4,255	-
Age < 1	40%	30%	10%	-

Age 1 to <2	12%	11%	2%	-
Age 2-4	17%	-	-	-
Age 5-9	15%	-	-	-
Age 10-18	16%	-	-	-
Boy	57%	58%	-1%	-
Died	1%	2%	-1%	-
LRTI hospitalizations = 0	94%	100%	-5%	-
Underlying chronic medical conditions = 0	24%	51%	-27%	-
Underlying chronic medical conditions >= 1	76%	49%	27%	-
Underlying medical conditions = 1	38%	23%	15%	-
Underlying medical conditions = 2	21%	11%	9%	-
Underlying medical conditions >=3	17%	15%	2%	-
Asthma	20%	16%	4%	-
Other pulmonary diseases	56%	18%	38%	-
Cardiac disease	18%	12%	6%	-
Renal disease	1%	1%	0%	-
Hemoglobinopathies	3%	2%	1%	-
HIV/AIDS	0%	0%	0%	-
Immunosuppression	3%	3%	0%	-
Malignancy	3%	3%	-1%	-
Diabetes	2%	1%	1%	-
Other metabolic disorder	2%	3%	-0%	-
Obesity	1%	1%	0%	-
Liver disease	0%	1%	-0%	-
Neurologic disorder	16%	16%	-0%	-
Cerebrovascular disease	2%	2%	0%	-
Pregnancy complications	3%	1%	2%	-
Prematurity	3%	18%	-16%	-

Other congenital disorder	6%	6%	-0%	-
---------------------------	----	----	-----	---

Study Rep 23

Comparison of Table 1 Values for Study Rep 23

Variable	Study	Aet	Diff	Std Diff
Number of subjects	104,453	124,973	-20,520	-
Age <1	33%	20%	13%	-
Age 1 to <2	17%	16%	1%	-
Age 2-4	22%	-	-	-
Age 5-9	16%	-	-	-
Age 10-18	12%	-	-	-
Boy	57%	56%	0%	-
Died	0%	0%	-0%	-
LRTI hospitalizations = 0	96%	100%	-4%	-
Underlying medical conditions = 0	54%	59%	-4%	-
Underlying medical conditions >= 1	46%	41%	4%	-
Underlying medical conditions = 1	30%	25%	5%	-
Underlying medical conditions = 2	10%	9%	0%	-
Underlying medical conditions >=3	6%	7%	-1%	-
Asthma	19%	18%	1%	-
Other pulmonary diseases	22%	3%	19%	-
Cardiac disease	6%	5%	1%	-
Renal disease	0%	0%	0%	-

Hemoglobinopathies	2%	2%	-0%	-
HIV/AIDS	0%	0%	-0%	-
Immunosuppression	2%	2%	0%	-
Malignancy	1%	2%	-1%	-
Diabetes	1%	1%	0%	-
Other metabolic disorder	1%	2%	-1%	-
Obesity	0%	1%	-0%	-
Liver disease	0%	0%	-0%	-
Neurologic disorder	7%	9%	-2%	-
Cerebrovascular disease	1%	1%	-0%	-
Pregnancy complications	2%	1%	1%	-
Prematurity	6%	3%	3%	-
Other congenital disorder	2%	3%	-1%	-

Study Rep 24

Comparison of Table 1 Values for Study Rep 24

Variable	Study	Aet	Diff	Std Diff
Number of subjects	1,325	6,716	-5,391	-
Continuous enrollment mean (SD)	44.8	-	-	-
Male	59%	71%	-12%	-
Female	41%	29%	12%	-
Age <18	-	0%	-	-
Age 18-34	-	3%	-	-

Age 35-49	-	15%	-	-
Age 50-64	-	58%	-	-
Age 65-80	94%	22%	72%	-
Age >80	6%	2%	4%	-
Commercial care	-	76%	-	-
Medicare	100%	24%	76%	-
Northeast	6%	17%	-11%	-
North Central	37%	28%	9%	-
South	33%	34%	-1%	-
West	23%	18%	5%	-
Unknown Region	0%	3%	-3%	-
Any pharmaceutical info available	99%	-	-	-
Any pharmaceutical info not available	1%	-	-	-
Procedure year 2005	11%	-	-	-
Procedure year 2006	21%	-	-	-
Procedure year 2007	27%	-	-	-
Procedure year 2008	32%	-	-	-
Procedure year 2009	9%	-	-	-
Length of stay = 0	40%	0%	40%	-
Length of stay =1	38%	-	-	-
Length of stay =2-4	15%	-	-	-
Length of stay =5-9	5%	-	-	-
Length of stay =10-19	1%	-	-	-
Length of stay =20+	0%	0%	0%	-
Inpatient	60%	58%	2%	-
Outpatient	40%	58%	-18%	-
Ischemic with myocardial infarction	5%	6%	-1%	-
Ischemic without myocardial infarction	54%	33%	21%	-

Heart failure	25%	17%	8%	-
Cardiomyopathy	11%	14%	-3%	-
Hypertensive heart disease without heart failure	9%	6%	3%	-
Valvular heart disease	41%	30%	11%	-
Conduction system disease	10%	13%	-3%	-
Congenital heart disease	4%	4%	-0%	-
Hypertension	68%	59%	9%	-
Diabetes	21%	17%	4%	-
COPD	18%	9%	9%	-
Acute renal failure	3%	-	-	-

Comparison of Health Results for Study Rep 24 (RS21)

Basic Parameters

Outcome	Parameter	Study Exp	Action Exp	Study Ref	Action Ref
Acute safety composite outcome	Number of outcomes	564	236	161	677
Acute safety composite outcome	Number of patients	4,622	1,666	1,325	5,050
Acute safety composite outcome	Number of person-years	-	28	-	86
Acute safety composite outcome	Risk per 1000	122.03	141.66	121.51	134.06
Acute safety composite outcome	Incidence rate per 1000	-	8,380.19	-	7,829.81

Treatment Effect Estimates

Outcome	Parameter	Study Value	Study CI	Action Value	Action CI
Acute safety composite outcome	Unadjusted estimate	1.00	(0.96, 1.04)	1.07	(0.91, 1.23)
Acute safety composite outcome	Adjusted estimate	1.05	(0.85, 1.29)	-	(-, -)

Study Rep 25

Comparison of Table 1 Values for Study Rep 25

Variable	Study	Aet	Diff	Std Diff
Number of subjects	105,682	179,028	-73,346	-
Age, mean (SD)	59.2	58.4	0.8	0.1
Quan-Charlson Comorbidity index, Mean (SD)	1.3	1.3	0.0	0.0
DVT only	59%	-	-	-
PE with or without DVT	41%	38%	3%	-
Cancer at baseline	17%	19%	-2%	-
Provoked VTE	28%	33%	-5%	-
Unprovoked VTE	55%	48%	7%	-
Female	49%	50%	-0%	-
Northeast	15%	17%	-2%	-
Midwest	33%	31%	2%	-
South	34%	33%	0%	-
West	17%	17%	-0%	-
Unknown Region	1%	1%	-0%	-
PPO	53%	54%	-1%	-
Comprehensive	15%	15%	0%	-
HMO	14%	14%	1%	-
POS	6%	6%	0%	-
CDHP	3%	3%	0%	-
EPO	1%	1%	0%	-
POS capitated	0%	0%	0%	-
Other Insurance	6%	7%	-1%	-

Quan-Charlson Comorbidity index=0	52%	50%	2%	-
Quan-Charlson Comorbidity index=1	18%	19%	-1%	-
Quan-Charlson Comorbidity index=2	12%	13%	-1%	-
Quan-Charlson Comorbidity index.=3	18%	18%	-0%	-
Use of anticoagulant at baseline	12%	34%	-22%	-
2007 Index	8%	-	-	-
2008 Index	18%	10%	8%	-
2009 Index	21%	20%	1%	-
2010 Index	21%	19%	2%	-
2011 Index	23%	22%	2%	-
2012 Index	10%	21%	-12%	-
Major surgery	73%	-	-	-
Age >60 years	49%	43%	6%	-
Hypertension	37%	40%	-3%	-
Hyperlipidemia	24%	26%	-3%	-
Multiple trauma	23%	32%	-9%	-
Malignant cancer	17%	19%	-2%	-
Diabetes	16%	17%	-1%	-
Other serious infection	14%	-	-	-
Chronic obstructive pulmonary disease	9%	10%	-1%	-
Pneumonia	7%	7%	-0%	-
Contraceptive pill (use of oral)	6%	3%	2%	-
Obesity	5%	7%	-2%	-
Hip, pelvis, or leg fracture	5%	3%	2%	-
Tobacco	4%	5%	-1%	-
Central venous catheter	4%	6%	-2%	-
Total knee replacement	2%	2%	-0%	-
Varicose veins	2%	3%	-1%	-

Treatment with erythropoiesis stimulating agents	2%	0%	1%	-
Rheumatoid arthritis	2%	2%	-0%	-
Coagulation defect	2%	4%	-2%	-
Inflammatory bowel disease	1%	1%	-0%	-
Surgical resection of abdominal or pelvic cancer	1%	-	-	-
Pregnancy	1%	1%	-0%	-
Thrombophilia	1%	2%	-1%	-
Total hip replacement	1%	1%	0%	-
Treatment with SERMs	1%	1%	0%	-
Spinal cord injury	0%	1%	-1%	-
Treatment with aromatase inhibitors	0%	1%	-1%	-
Immobility	0%	0%	0%	-
Abdominal surgery	0%	3%	-3%	-

Study Rep 26

Comparison of Table 1 Values for Study Rep 26

Variable	Study				Ref			Diff of Diff
	Exp	Aet Exp	Exp Diff	Std Diff	Ref	Aet Ref	Ref Diff	
Number of subjects	744	1,357	-613	-	1,851	3,012	-1,161	- 548
Age, mean (SD)	43.7	46.3	-2.6	-0.2	43.2	41.4	1.8	0.1 -4.4
Comorbidity Deyo-Charlson Comorbidity Index	0.3	0.8	-0.5	-0.4	0.7	0.4	0.3	0.2 -0.7
Comorbidity Unique 3-digit ICD-9-CM diagnoses, mean (SD)	6.0	-	-	-	7.7	-	-	- -

Comorbidity Unique outpatient medications, mean (SD)	6.7	-	-	-	7.1	-	-	-	-
age 18-24	8%	9%	-2%	-	13%	17%	-4%	-	3%
age 25-34	14%	12%	2%	-	18%	17%	1%	-	1%
age 35-44	21%	16%	5%	-	23%	19%	3%	-	1%
age 45-54	31%	29%	2%	-	27%	25%	2%	-	-1%
age 55-65	26%	33%	-6%	-	19%	22%	-3%	-	-4%
Male	32%	33%	-1%	-	41%	44%	-3%	-	3%
Female	68%	67%	1%	-	59%	56%	3%	-	-3%
Northeast	8%	14%	-6%	-	12%	15%	-3%	-	-3%
North Central	26%	28%	-2%	-	32%	31%	1%	-	-3%
South	47%	40%	7%	-	39%	34%	6%	-	2%
West	17%	16%	1%	-	16%	18%	-2%	-	4%
Unknown Region	2%	2%	-0%	-	1%	2%	-1%	-	0%
Comprehensive Insurance	14%	8%	6%	-	12%	6%	6%	-	-0%
HMO	14%	13%	1%	-	18%	15%	3%	-	-2%
POS	9%	9%	-0%	-	11%	9%	2%	-	-2%
POS with capitation	59%	64%	-6%	-	53%	64%	-11%	-	5%
Other Insurance	4%	5%	-2%	-	5%	6%	-1%	-	-1%
Depression	52%	56%	-4%	-	29%	29%	-0%	-	-3%
Hyperlipidemia	10%	6%	4%	-	7%	5%	2%	-	2%
Anxiety/panic disorders	14%	14%	0%	-	7%	6%	0%	-	-0%
Renal disease	4%	3%	1%	-	3%	1%	1%	-	-0%
Fibromyalgia	9%	10%	-1%	-	2%	2%	-0%	-	-1%
Antidepressants	48%	52%	-4%	-	24%	27%	-3%	-	-1%
Anxiolytics	52%	62%	-10%	-	23%	22%	1%	-	-11%
Antihypertensives	22%	-	-	-	12%	-	-	-	-
Statins	19%	24%	-5%	-	11%	15%	-4%	-	-1%

Bone density agents	6%	6%	0%	-	4%	4%	0%	-	-0%
Antidiabetics	10%	5%	4%	-	5%	2%	3%	-	2%

Comparison of Health Results for Study Rep 26 (RS23)

Basic Parameters

Outcome	Parameter	Study Exp	Action Exp	Study Ref	Action Ref
Any inpatient visit	Number of outcomes	413	373	827	499
Any inpatient visit	Number of patients	744	1,357	1,851	3,012
Any inpatient visit	Number of person-years	-	1,139	-	2,722
Any inpatient visit	Risk per 1000	555.11	274.87	446.79	165.67
Any inpatient visit	Incidence rate per 1000	-	327.33	-	183.29

Treatment Effect Estimates

Outcome	Parameter	Study Value	Study CI	Action Value	Action CI
Any inpatient visit	Unadjusted estimate	1.36	(1.21, 1.54)	1.91	(1.76, 2.06)
Any inpatient visit	Adjusted estimate	-	(-, -)	1.28	(1.10, 1.46)

Study Rep 27

Comparison of Table 1 Values for Study Rep 27

Variable	Study	Aet	Diff	Std Diff
Number of subjects	1,240	1,165	75	-
Age	45.9	43.8	2.1	0.1
Doxorubicin	0%	0%	0%	-

Dexamethasone	12%	10%	3%	-
Prednisone	14%	23%	-9%	-
Rituximab	0%	0%	0%	-
Thalidomide	0%	0%	0%	-
Cyclophosphamide	0%	0%	0%	-
Tocilizumab	0%	0%	0%	-
Male	38%	35%	3%	-
Female	62%	65%	-3%	-
Age < 40	32%	36%	-4%	-
Age 40-64	58%	55%	3%	-
Age >=65	10%	9%	1%	-
Cancer	4%	5%	-1%	-
Lupus	1%	1%	-0%	-
RA	0%	1%	-0%	-
HIV	0%	0%	0%	-
Herpes (HHV-8)	0%	0%	0%	-
Kaposi sarcoma	0%	0%	0%	-

Study Rep 28

Comparison of Table 1 Values for Study Rep 28

Variable	Study	Aet	Diff	Std Diff
Age Mean (SD), Median (Males)	49.0	44.2	4.8	0.3
Age Mean (SD), Median (Females)	49.8	44.2	5.6	0.4

Number of subjects (% of CD parent cohort)	23%	-	-	-
Male	33%	29%	5%	-
Female	67%	71%	-5%	-

Study Rep 29

Comparison of Table 1 Values for Study Rep 29

Variable	Study	Aet	Diff	Std Diff
Number of subjects	7,971	16,745	-8,774	-
Age (meanSD)	67.8	69.4	-1.6	-0.1
Warfarin daily dose (meanSD)	2.8	-	-	-
CHADS2 score (meanSD)	1.6	1.8	-0.2	-0.1
age 18-<65	41%	36%	5%	-
age 65-<75	25%	25%	-0%	-
age 75-585	26%	30%	-3%	-
Age 85+	8%	9%	-1%	-
Male	59%	60%	-1%	-
Female	41%	40%	1%	-
Bleeding	7%	4%	4%	-
Potentiating concomitant medications influencing efficacy of warfarin	47%	-	-	-
Inhibiting concomitant medications influencing efficacy of warfarin	7%	-	-	-
Potentiating & inhibiting concomitant medications influencing efficacy of warfarin	23%	-	-	-
Warfarin <=5 mg/day	90%	96%	-6%	-

Warfarin 5-7 mg/day	8%	1%	7%	-
Warfarin >7 mg/day	2%	4%	-2%	-
Proton pump inhibitors	21%	20%	1%	-
H2 antagonists	3%	3%	-0%	-
Prostaglandin E1 analogs/protectants	0%	5%	-5%	-
CHADS2=0	21%	17%	4%	-
CHADS2=1	32%	31%	2%	-
CHADS2=2-3	37%	28%	9%	-
CHADS2=4	10%	11%	-1%	-
Stroke	16%	14%	1%	-
Cardiovascular disease	44%	42%	2%	-
Hypertension	51%	61%	-10%	-
Anemia	8%	9%	-1%	-
Diabetes	22%	25%	-3%	-
GI disorders	19%	24%	-4%	-

Study Rep 30

Comparison of Table 1 Values for Study Rep 30

Variable	Study	Aet	Diff	Std Diff
Number of subjects	-	16,745	-	-
Age (meanSD)	67.7	69.4	-1.7	-0.1
Warfarin daily dose (meanSD)	2.3	-	-	-

CHADS2 score (meanSD)	1.6	1.8	-0.2	-0.1
age 18-<65	40%	-	-	-
age 65-<75	25%	-	-	-
age 75-585	26%	-	-	-
Age 85+	9%	-	-	-
Male	60%	-	-	-
Female	40%	-	-	-
Bleeding	8%	4%	4%	-
Potentiating concomitant medications influencing efficacy of warfarin	46%	-	-	-
Inhibiting concomitant medications influencing efficacy of warfarin	7%	-	-	-
Potentiating & inhibiting concomitant medications influencing efficacy of warfarin	21%	-	-	-
Warfarin <=5 mg/day	97%	96%	1%	-
Warfarin 5-7 mg/day	2%	1%	1%	-
Warfarin >7 mg/day	0%	4%	-3%	-
Proton pump inhibitors	19%	20%	-1%	-
H2 antagonists	3%	3%	-0%	-
Prostaglandin E1 analogs/protectants	50%	5%	45%	-
CHADS2=0	22%	17%	5%	-
CHADS2=1	32%	31%	2%	-
CHADS2=2-3	36%	28%	8%	-
CHADS2=4	9%	11%	-2%	-
Stroke	15%	14%	0%	-
Cardiovascular disease	46%	42%	4%	-
Hypertension	50%	61%	-11%	-
Anemia	9%	9%	-0%	-
Diabetes	21%	25%	-5%	-
GI disorders	20%	24%	-4%	-

Study Rep 31

Comparison of Table 1 Values for Study Rep 31

Variable	Study Exp	Aet Exp	Exp Diff	Exp Std Diff	Study Ref	Aet Ref	Ref Diff	Ref Std Diff	Diff of Diff
Number of subjects	67,901	74,049	-6,148	-	115,491	118,186	-2,695	-	-3,453
Age: mean (sd)	58.0	57.4	0.6	0.0	61.0	60.0	1.0	0.0	-0.4
BMI: mean (sd)	26.0	26.0	0.0	0.0	26.0	25.9	0.1	0.0	-0.1
Prevalent users	40%	40%	0%	-	35%	37%	-2%	-	3%
Female	56%	56%	-0%	-	60%	61%	-1%	-	1%
Male	44%	44%	0%	-	40%	39%	1%	-	-1%
Age 18-29	14%	14%	-0%	-	8%	9%	-1%	-	1%
Age 30-39	14%	15%	-1%	-	12%	13%	-1%	-	1%
Age 40-49	14%	14%	-0%	-	13%	14%	-1%	-	1%
Age 50-59	10%	10%	-0%	-	13%	13%	0%	-	-0%
Age 60-69	8%	8%	-0%	-	12%	11%	1%	-	-1%
Age 70-79	14%	14%	-0%	-	16%	15%	1%	-	-1%
Age 80+	27%	25%	2%	-	26%	25%	1%	-	0%
Nonsmoker	38%	41%	-3%	-	38%	40%	-2%	-	-1%
Ex-smoker	18%	14%	3%	-	15%	12%	3%	-	-0%
Smoker	30%	30%	1%	-	27%	27%	0%	-	1%
Unknown smoking status	14%	-	-	-	19%	-	-	-	-
Schizophrenia	13%	14%	-1%	-	6%	7%	-1%	-	0%
Bipolar/other mood disorders	6%	7%	-1%	-	3%	3%	-1%	-	-0%

Major depression	12%	14%	-2%	-	10%	11%	-1%	-	-1%
Dementia	18%	17%	2%	-	11%	10%	1%	-	1%
No recorded specific psychiatric disorders	50%	53%	-3%	-	70%	71%	-1%	-	-2%
History of alcoholism or drug abuse	12%	11%	1%	-	10%	9%	1%	-	0%
History of suicide attempts	7%	8%	-0%	-	5%	5%	-0%	-	0%
Diabetes mellitus	8%	9%	-1%	-	8%	8%	0%	-	-1%
Acute MI	3%	3%	0%	-	4%	3%	0%	-	-0%
statins/fibrates in the 3 mos prior	12%	12%	-0%	-	7%	7%	0%	-	-0%
Antiplatelets	20%	20%	-0%	-	16%	17%	-0%	-	0%
Antidepressants	50%	52%	-1%	-	43%	45%	-2%	-	1%
Anxiolytics	17%	17%	-0%	-	14%	14%	-0%	-	0%
SSRIs	30%	31%	-1%	-	21%	23%	-2%	-	0%
Lithium	3%	4%	-0%	-	2%	3%	-0%	-	0%
Antiepileptics	6%	6%	-0%	-	5%	5%	-0%	-	-0%

Comparison of Health Results for Study Rep 31 (RS27)

Basic Parameters

Outcome	Parameter	Study Exp	Aetion Exp	Study Ref	Aetion Ref
Death	Number of outcomes	7,555	5,411	15,334	9,614
Death	Number of patients	67,901	74,049	115,491	118,186
Death	Number of person-years	99,407	58,983	167,584	71,460
Death	Risk per 1000	111.26	73.07	132.77	81.35
Death	Incidence rate per 1000	76.00	91.74	91.50	134.54

Treatment Effect Estimates

Outcome	Parameter	Study Value	Study CI	Action Value	Action CI
Death	Unadjusted estimate	0.83	(0.81, 0.85)	0.68	(0.65, 0.72)
Death	Adjusted estimate	0.83	(0.80, 0.85)	0.71	(0.67, 0.74)

Study Rep 32

Comparison of Table 1 Values for Study Rep 32

Variable	Study	Aet	Diff	Std Diff
Number of subjects	1,026	127,749	-126,723	-
Average HbA1c level during the 1-year study period, mean, in % NGSP units	7.3	-	-	-
Age, Mean (SD)	55.3	57.2	-1.9	-0.2
No. of different hypoglycemic drug classes, Mean (SD)	3.0	2.4	0.6	0.5
Average HbA1c mmol/mol IFCC units, Mean (SD)	56.0	-	-	-
Percentage of time within glycemic goal (i.e., HbA1c <7%), Mean (SD)	49.7	-	-	-
Charlson comorbidity index (without diabetes), Mean (SD)	1.3	1.0	0.3	0.2
Treatment gaps ?90 consecutive days	11%	-	-	-
Proportion of days of use during the period	20%	-	-	-
Used hypoglycemic agents for more than 80% of the period	75%	-	-	-
Female	47%	48%	-1%	-
Region, Northeast	13%	13%	-1%	-
Region, North Central	23%	27%	-4%	-
Region, South	54%	45%	8%	-
Region, West	11%	12%	-1%	-

Insurance plan type, Comprehensive Insurance	6%	7%	-1%	-
Insurance plan type, Non-Capitated Point-of-Service (POS)	20%	10%	9%	-
Insurance plan type, Preferred Provider Organization (PPO)	69%	77%	-7%	-
Insurance plan type, Consumer-Driven Health Plan (CDHP)	4%	4%	-1%	-
Insurance plan type, High Deductible Health Plan (HDHP)	1%	2%	-1%	-
Alpha-Glucosidase Inhibitors	1%	1%	0%	-
Hypoglycemic Agents - Amylin Analogs	1%	2%	-1%	-
Hypoglycemic Agent Combinations	22%	20%	2%	-
Biguanide Sensitizers	66%	67%	-0%	-
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors	19%	23%	-4%	-
Human Insulin	41%	38%	3%	-
Incretin Mimetic Agents (GLP-1 Receptor Agonists)	17%	18%	-2%	-
Meglitinide Analogues	2%	4%	-2%	-
Sulfonylureas	43%	43%	0%	-
Thiazolidinediones (TZDs)	31%	29%	2%	-
Other hypoglycemic agents	4%	0%	4%	-
>=2 different hypoglycemic drug classes	88%	73%	15%	-
>=3 different hypoglycemic drug classes	62%	37%	24%	-
Use of bile acid sequestrants	3%	3%	-0%	-
Within glycemic goal (i.e., HbA1c level <7% NGSP [<53 mmol/mol IFFC] at the index date	47%	-	-	-
Diabetic retinopathy	16%	9%	7%	-
Nephropathy	17%	8%	9%	-
Neuropathy	23%	18%	5%	-
Atherosclerosis, aneurysm, or embolism	7%	27%	-20%	-
Peripheral vascular conditions	15%	6%	9%	-
Cerebrovascular disease	11%	8%	3%	-
Coronary artery disease	30%	23%	6%	-
Infections	24%	29%	-6%	-

Other ocular complications	24%	14%	10%	-
Ulceration or diabetic bone changes	5%	8%	-4%	-
Ketoacidosis or hyperosmolarity	1%	1%	-0%	-
Hypoglycemia	7%	2%	5%	-
Diabetic coma	1%	0%	1%	-
Unspecified diabetes-related complication	8%	-	-	-
IP admission related to a complication	20%	-	-	-
ER visit related to a complication	5%	-	-	-
Patients seen by an endocrinologist	19%	-	-	-
Hypertension and associated conditions	66%	76%	-10%	-
Lipid disorders	70%	73%	-3%	-
Congestive heart failure	8%	7%	1%	-
Overweight, obesity	11%	17%	-6%	-
Mental disorder	11%	3%	9%	-
Other genitourinary system disorder	24%	22%	2%	-
AIDS	1%	0%	1%	-
Anemia	18%	18%	0%	-
Chronic pulmonary disease	15%	10%	5%	-
Coagulopathy	4%	2%	1%	-
Fluid electrolyte disorders	10%	10%	-0%	-
Hypothyroidism	18%	17%	1%	-
Liver disease	7%	6%	2%	-
Cancer	13%	12%	1%	-
Other neurological disorders	6%	10%	-4%	-
Paralysis	1%	0%	0%	-
Psychoses	9%	8%	0%	-
Pulmonary circulation disorders	3%	0%	3%	-
Rheumatoid arthritis	7%	2%	4%	-

Valvular disease	5%	8%	-4%	-
Alcohol abuse	0%	6%	-6%	-
Drug abuse	0%	5%	-5%	-
Smoker	2%	4%	-2%	-
Weight loss	2%	2%	0%	-

Study Rep 33

Comparison of Table 1 Values for Study Rep 33

Variable	Study	Aet	Diff	Std Diff
Number of subjects	3,078	106,457	-103,379	-
Average HbA1c level during the 1-year study period, mean, in % NGSP units	7.2	-	-	-
Age, Mean (SD)	53.4	54.9	-1.5	-0.2
No. of different hypoglycemic drug classes, Mean (SD)	1.8	2.0	-0.2	-0.2
Average HbA1c mmol/mol IFCC units, Mean (SD)	55.0	-	-	-
Percentage of time within glyceimic goal (i.e., HbA1c <7%), Mean (SD)	50.6	-	-	-
Charlson comorbidity index (without diabetes), Mean (SD)	0.3	0.3	0.0	0.0
Treatment gaps ?90 consecutive days	13%	-	-	-
Proportion of days of use during the period	21%	-	-	-
Used hypoglycemic agents for more than 80% of the period	71%	-	-	-
Female	41%	44%	-3%	-
Region, Northeast	11%	12%	-1%	-
Region, North Central	19%	25%	-6%	-

Region, South	60%	49%	11%	-
Region, West	10%	12%	-2%	-
Insurance plan type, Comprehensive Insurance	4%	5%	-1%	-
Insurance plan type, Non-Capitated Point-of-Service (POS)	21%	10%	11%	-
Insurance plan type, Preferred Provider Organization (PPO)	70%	78%	-8%	-
Insurance plan type, Consumer-Driven Health Plan (CDHP)	3%	4%	-1%	-
Insurance plan type, High Deductible Health Plan (HDHP)	1%	2%	-1%	-
Alpha-Glucosidase Inhibitors	1%	1%	0%	-
Hypoglycemic Agents - Amylin Analogs	0%	0%	0%	-
Hypoglycemic Agent Combinations	27%	19%	7%	-
Biguanide Sensitizers	69%	75%	-5%	-
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors	16%	16%	0%	-
Human Insulin	18%	16%	2%	-
Incretin Mimetic Agents (GLP-1 Receptor Agonists)	8%	8%	0%	-
Meglitinide Analogues	2%	2%	-0%	-
Sulfonylureas	40%	42%	-2%	-
Thiazolidinediones (TZDs)	29%	22%	7%	-
Other hypoglycemic agents	2%	0%	1%	-
>=2 different hypoglycemic drug classes	57%	57%	0%	-
>=3 different hypoglycemic drug classes	20%	22%	-3%	-
Use of bile acid sequestrants	2%	1%	0%	-
Within glycemic goal (i.e., HbA1c level <7% NGSP [<53 mmol/mol IFFC] at the index date	48%	-	-	-
Diabetic retinopathy	10%	4%	5%	-
Nephropathy	7%	4%	3%	-
Neuropathy	9%	7%	2%	-
Atherosclerosis, aneurysm, or embolism	2%	8%	-6%	-
Peripheral vascular conditions	5%	2%	3%	-
Cerebrovascular disease	3%	2%	1%	-

Coronary artery disease	8%	7%	1%	-
Infections	12%	16%	-4%	-
Other ocular complications	15%	8%	7%	-
Ulceration or diabetic bone changes	1%	3%	-2%	-
Ketoacidosis or hyperosmolarity	0%	1%	-0%	-
Hypoglycemia	2%	1%	1%	-
Diabetic coma	1%	0%	1%	-
Unspecified diabetes-related complication	4%	-	-	-
IP admission related to a complication	1%	-	-	-
ER visit related to a complication	1%	-	-	-
Patients seen by an endocrinologist	12%	-	-	-
Hypertension and associated conditions	56%	65%	-9%	-
Lipid disorders	68%	70%	-1%	-
Congestive heart failure	1%	1%	-0%	-
Overweight, obesity	5%	8%	-3%	-
Mental disorder	4%	0%	3%	-
Other genitourinary system disorder	10%	12%	-2%	-
AIDS	0%	0%	-0%	-
Anemia	6%	6%	-1%	-
Chronic pulmonary disease	6%	4%	3%	-
Coagulopathy	1%	0%	0%	-
Fluid electrolyte disorders	2%	2%	-1%	-
Hypothyroidism	11%	11%	-0%	-
Liver disease	1%	2%	-1%	-
Cancer	3%	4%	-1%	-
Other neurological disorders	1%	3%	-2%	-
Paralysis	0%	0%	0%	-
Psychoses	2%	2%	-0%	-

Pulmonary circulation disorders	0%	0%	0%	-
Rheumatoid arthritis	1%	1%	1%	-
Valvular disease	2%	2%	-0%	-
Alcohol abuse	0%	2%	-2%	-
Drug abuse	0%	2%	-2%	-
Smoker	1%	2%	-1%	-
Weight loss	0%	1%	-0%	-

Study Rep 34

Comparison of Table 1 Values for Study Rep 34

Variable	Study			Exp	Study			Ref	
	Exp	Aet Exp	Exp Diff	Std Diff	Ref	Aet Ref	Ref Diff	Std Diff	Diff of Diff
Number of subjects	654	6,647	-5,993	-	654	4,185	-3,531	-	-2,462
Modified CCI (mean, SD)	1.1	1.7	-0.5	-0.3	1.1	1.8	-0.7	-0.5	0.2
OAD MPR (mean, SD)	0.7	-	-	-	0.7	-	-	-	-
A1C % (mean, SD)	9.4	-	-	-	9.5	-	-	-	-
Total healthcare costs, all-cause (mean, SD)	10,442.0	15,070.0	-4,628.0	-0.1	10,069.0	24,279.3	-14,210.3	-0.3	9,582.3
Total healthcare costs, diabetes-related (mean, SD)	3,739.0	6,412.5	-2,673.5	-0.2	3,662.0	8,983.1	-5,321.1	-0.3	2,647.5
Age category, 18-39	7%	9%	-2%	-	7%	8%	-2%	-	-0%
Age category, 40-64	84%	85%	-1%	-	86%	83%	3%	-	-4%

Age category, 65-74	8%	5%	3%	-	6%	7%	-1%	-	4%
Age category, 75+	1%	1%	-0%	-	0%	2%	-1%	-	1%
Female	43%	44%	-1%	-	44%	45%	-1%	-	0%
Plan type, HMO	15%	15%	0%	-	18%	11%	7%	-	-7%
Plan type, POS	54%	62%	-8%	-	49%	57%	-8%	-	0%
Plan type, PPO	13%	8%	5%	-	12%	16%	-3%	-	9%
Plan type, Other	18%	16%	2%	-	20%	16%	4%	-	-2%
Any hypoglycemia	3%	3%	-0%	-	4%	5%	-1%	-	1%
Metformin	60%	64%	-4%	-	62%	62%	0%	-	-4%
Sulfonylureas	61%	68%	-6%	-	64%	63%	1%	-	-7%
DPP-4 inhibitor	24%	27%	-3%	-	25%	20%	5%	-	-8%
GLP-1 receptor analog	14%	20%	-5%	-	14%	11%	3%	-	-9%
Thiazolidinedione	37%	38%	-2%	-	35%	35%	-0%	-	-2%
Pramlintide	0%	0%	0%	-	0%	0%	0%	-	0%
?-glucosidase inhibitor	1%	1%	0%	-	1%	1%	-0%	-	0%
A1C < 7.0%	12%	-	-	-	10%	-	-	-	-
A1C >=7.0-8.0%	16%	-	-	-	16%	-	-	-	-
A1C >=8.0-9.0%	19%	-	-	-	19%	-	-	-	-
A1C >=9.0%	53%	-	-	-	55%	-	-	-	-
All-cause ED visit	9%	7%	2%	-	9%	7%	2%	-	0%
All-cause inpatient admission	14%	11%	3%	-	14%	19%	-4%	-	7%
Diabetes-related ED visit	3%	2%	1%	-	3%	2%	1%	-	1%
Diabetes-related inpatient admission	10%	8%	2%	-	10%	13%	-2%	-	5%

Study Rep 35

Comparison of Table 1 Values for Study Rep 35

Variable	Study Exp	Aet Exp	Exp Diff	Exp Std Diff	Study Ref	Aet Ref	Ref Diff	Ref Std Diff	Diff of Diff
Number of patients	4,092	5,252	-1,160	-	10,320	13,457	-3,137	-	1,977
Age 25-34	4%	4%	-0%	-	33%	33%	0%	-	-1%
Age 35-44	46%	45%	1%	-	55%	55%	0%	-	1%
Age 45-54	50%	51%	-1%	-	12%	12%	-1%	-	-0%
Region Northeast	14%	19%	-5%	-	14%	20%	-6%	-	1%
Region Midwest	19%	19%	-1%	-	15%	15%	-0%	-	-0%
Region South	52%	45%	8%	-	55%	47%	8%	-	-0%
Region West	14%	14%	-0%	-	16%	16%	-0%	-	0%
Region Unknown	1%	2%	-2%	-	1%	2%	-1%	-	-1%
Plan type Fee for service	4%	3%	1%	-	3%	3%	0%	-	1%
Plan type HMO	29%	23%	6%	-	24%	18%	6%	-	-1%
Plan type Point of Service (POS)	13%	10%	3%	-	15%	10%	5%	-	-2%
Plan type Preferred Provider Organization	48%	55%	-7%	-	52%	60%	-9%	-	1%
Plan type Capitated POS	2%	1%	1%	-	2%	1%	1%	-	-0%
Plan type Consumer Driven Health Plan (CDHP)	2%	5%	-2%	-	3%	5%	-2%	-	-0%
Year of index date 2009	27%	-	-	-	24%	-	-	-	-
NSAIDs (non-steroidal anti- inflammatories)	28%	27%	0%	-	25%	25%	0%	-	0%
Hormone therapy	31%	7%	24%	-	40%	9%	31%	-	-7%
Any inpatient visits	6%	5%	1%	-	7%	7%	0%	-	0%

Menstrual disorders	56%	60%	-3%	-	46%	47%	-1%	-	-2%
Pelvic pain	24%	29%	-5%	-	31%	38%	-7%	-	2%
Anemias	28%	33%	-4%	-	18%	22%	-4%	-	0%
Inflammatory disease	14%	16%	-2%	-	18%	20%	-1%	-	-0%
Noninflammatory disease	14%	19%	-5%	-	18%	24%	-6%	-	1%
Endometriosis	2%	3%	-1%	-	5%	8%	-3%	-	2%
Pregnancy	3%	3%	0%	-	15%	14%	1%	-	-1%
Urinary problems	3%	7%	-3%	-	4%	5%	-1%	-	-2%
Constipation or gas	3%	4%	-1%	-	3%	4%	-1%	-	-0%
Other disorders of the uterus	19%	22%	-3%	-	13%	17%	-4%	-	1%
Genital prolapse	0%	1%	-0%	-	1%	1%	-0%	-	0%
Benign neoplasm of the uterus	0%	0%	-0%	-	0%	1%	-1%	-	1%
Infertility	1%	1%	0%	-	15%	16%	-1%	-	1%
Breast cancer	1%	1%	-0%	-	0%	1%	-0%	-	0%

Study Rep 36

Comparison of Table 1 Values for Study Rep 36

Variable	Study				Ref				
	Study Exp	Aet Exp	Exp Diff	Std Diff	Study Ref	Aet Ref	Ref Diff	Std Diff	Diff of Diff
Number of subjects	17,428	17,667	-239	-	32,890	87,889	-54,999	-	54,760
No. of psychiatric diagnoses, Mean (SD), Median	1.2	-	-	-	1.3	-	-	-	-
Male	45%	48%	-3%	-	32%	32%	0%	-	-3%

Female	55%	52%	3%	-	68%	68%	-0%	-	3%
age 18-24	11%	17%	-6%	-	13%	14%	-1%	-	-5%
age 25-34	13%	13%	0%	-	15%	14%	1%	-	-1%
age 35-44	22%	19%	3%	-	24%	23%	1%	-	2%
age 45-54	30%	26%	4%	-	28%	28%	1%	-	3%
age 55-64	23%	24%	-1%	-	19%	21%	-2%	-	1%
CDHP insurance	1%	4%	-2%	-	2%	4%	-2%	-	-1%
COMP insurance	10%	4%	5%	-	5%	3%	2%	-	3%
EPO insurance	1%	1%	-1%	-	1%	1%	-0%	-	-0%
HMO insurance	21%	18%	4%	-	17%	16%	1%	-	3%
POS without capitation insurance	10%	8%	2%	-	10%	8%	1%	-	1%
POS with capitation insurance	2%	0%	1%	-	1%	1%	0%	-	1%
PPO insurance	54%	60%	-6%	-	62%	62%	0%	-	-6%
index 2003-2005	49%	-	-	-	11%	-	-	-	-
index 2006-2008	37%	11%	26%	-	43%	8%	34%	-	-8%
index 2009-2010	14%	40%	-26%	-	47%	43%	4%	-	-30%
Northeast	11%	18%	-7%	-	12%	17%	-5%	-	-2%
North central	28%	25%	3%	-	29%	25%	3%	-	-1%
South	36%	33%	3%	-	42%	38%	4%	-	-1%
West	25%	22%	2%	-	17%	18%	-1%	-	3%
Unknown Region	0%	2%	-1%	-	0%	2%	-2%	-	0%
Schizophrenia	4%	8%	-3%	-	2%	2%	0%	-	-4%
Dementia	1%	1%	-0%	-	0%	0%	0%	-	-0%
Bipolar Disorder	17%	29%	-12%	-	16%	20%	-4%	-	-8%
Major depressive disorder	40%	27%	13%	-	55%	40%	15%	-	-2%
All other Mental health conditions	46%	-	-	-	34%	-	-	-	-
Hypertension	16%	18%	-2%	-	14%	17%	-2%	-	0%

Peripheral vascular disease	0%	1%	-1%	-	0%	1%	-0%	-	-0%
hyperlipidemia	10%	12%	-3%	-	10%	12%	-2%	-	-1%
Obesity	1%	2%	-1%	-	3%	4%	-1%	-	0%
Charlson comorbidity score=0	81%	81%	-1%	-	85%	85%	-0%	-	-1%
Charlson comorbidity score=1-2	13%	15%	-2%	-	11%	13%	-2%	-	0%
Charlson comorbidity score=3-4	4%	1%	3%	-	3%	1%	3%	-	0%
Charlson comorbidity score>4	2%	3%	-0%	-	1%	1%	0%	-	-0%
Myocardial Infarction	0%	0%	0%	-	0%	0%	0%	-	0%
Stroke	2%	1%	1%	-	1%	0%	0%	-	0%
Heart Failure	1%	0%	0%	-	0%	0%	0%	-	0%

Comparison of Health Results for Study Rep 36 (RS33)

Basic Parameters

Outcome	Parameter	Study Exp	Action Exp	Study Ref	Action Ref
Myocardial infarction	Number of outcomes	59	20	44	63
Myocardial infarction	Number of patients	17,428	17,667	32,890	87,889
Myocardial infarction	Number of person-years	-	8,409	-	46,090
Myocardial infarction	Risk per 1000	3.39	1.13	1.34	0.72
Myocardial infarction	Incidence rate per 1000	-	2.38	-	1.37

Treatment Effect Estimates

Outcome	Parameter	Study Value	Study CI	Action Value	Action CI
Myocardial infarction	Unadjusted estimate	1.66	(1.40, 1.96)	1.73	(1.22, 2.23)
Myocardial infarction	Adjusted estimate	1.26	(0.85, 1.87)	1.45	(0.93, 1.98)

Study Rep 37

Comparison of Table 1 Values for Study Rep 37

Variable	Study	Aet	Diff	Std Diff
Number of patients	15,655	16,601	-946	-
endoscopy	4%	8%	-4%	-
Non-smoker	36%	52%	-15%	-
Former smoker	20%	22%	-2%	-
current smoker	10%	12%	-1%	-
Not recorded	34%	-	-	-
0 systemic steroid dispensings	67%	-	-	-
1-3 systemic steroid dispensing	14%	-	-	-
4 systemic steroid dispensings	19%	-	-	-
BMI <20	6%	9%	-3%	-
BMI 20 - 24	18%	29%	-11%	-
BMI 25 - 29	16%	23%	-7%	-
BMI 30 - 35	7%	9%	-2%	-
BMI 36+	3%	4%	-1%	-
BMI missing	50%	-	-	-

Study Rep 38

Comparison of Table 1 Values for Study Rep 38

Variable	Study	Aet	Diff	Std Diff
Number of subjects	21,976	225,643	-203,667	-
Age, Mean	56.1	-	-	-
Males	67%	-	-	-
Hypertension	48%	60%	-12%	-
Diabetes	22%	24%	-2%	-
Heart failure	12%	16%	-4%	-
Acute myocardial infarction	2%	2%	-0%	-
Coronary heart disease	20%	24%	-4%	-
Other arrhythmias	20%	31%	-11%	-
CHADS2 Score Category: Low Risk	42%	33%	9%	-
CHADS2 Score Category: Moderate Risk	36%	37%	-1%	-
CHADS2 Score Category: High Risk	22%	30%	-8%	-
CHADS2 VASc Score Category: Low Risk	22%	17%	5%	-
CHADS2 VASc Score Category: Moderate Risk	32%	29%	3%	-
CHADS2 VASc Score Category: High Risk	46%	54%	-8%	-

Study Rep 39

Comparison of Table 1 Values for Study Rep 39

Variable	Study	Aet	Diff	Std Diff
Number of patients	31,408	38,153	-6,745	-
Age <18	0%	0%	-0%	-

Age 18-29	0%	0%	-0%	-
Age 30-49	7%	7%	-1%	-
Age 50-64	39%	42%	-3%	-
Age 65-70	14%	12%	3%	-
Age 71+	40%	39%	1%	-
Female	40%	39%	1%	-
Northeast Region	12%	17%	-5%	-
Midwest Region	30%	28%	2%	-
South Region	39%	38%	0%	-
West Region	18%	16%	2%	-
Unknown Region	1%	1%	0%	-
Year of First Prescription 2009	14%	14%	1%	-
Year of First Prescription 2010	47%	44%	4%	-
Year of First Prescription 2011	38%	43%	-5%	-
Year of First Prescription 2012	0%	-	-	-
Enrollment 1-3 months	1%	-	-	-
Enrollment 4-6 months	1%	-	-	-
Enrollment 7-12 months	3%	1%	2%	-
Enrollment 13+ months	95%	98%	-3%	-

Study Rep 40

Comparison of Table 1 Values for Study Rep 40

Variable	Study	Aet	Diff	Std Diff
----------	-------	-----	------	----------

Number of patients	7,025	7,143	-118	-
Age <18	0%	0%	0%	-
Age 18-29	1%	1%	-0%	-
Age 30-49	12%	13%	-1%	-
Age 50-64	55%	56%	-1%	-
Age 65-70	15%	12%	3%	-
Age 71+	17%	18%	-1%	-
Female	31%	31%	0%	-
Northeast Region	9%	8%	0%	-
Midwest Region	24%	24%	0%	-
South Region	53%	53%	0%	-
West Region	14%	15%	-1%	-
Unknown Region	0%	0%	-0%	-
Year of First Prescription 2009	15%	15%	0%	-
Year of First Prescription 2010	43%	43%	0%	-
Year of First Prescription 2011	36%	36%	-0%	-
Year of First Prescription 2012	6%	6%	-0%	-
Enrollment 1-3 months	2%	9%	-6%	-
Enrollment 4-6 months	1%	3%	-2%	-
Enrollment 7-12 months	4%	7%	-3%	-
Enrollment 13+ months	92%	81%	12%	-